Podcasts about GIP

Chalene Johnson breaks down retatrutide, the peptide everyone is calling a GLP-3 and an Ozempic killer, cutting through the hype to get to what the science actually says. Eli Lilly's own clinical trials show weight loss results that beat anything semaglutide or tirzepatide has produced, but retatrutide is not FDA approved and is not legally available at any US pharmacy, which means almost nobody buying it online is actually getting the real thing. Chalene explains what retatrutide actually is (a triple agonist that adds glucagon receptor activity to the GLP-1 and GIP receptors already targeted by Ozempic, Wegovy, Mounjaro, and Zepbound), walks through what the phase three trial data really shows versus how it is being exaggerated online, and shares why an independent lab test of vials sold through TikTok, med spas, and Reddit found most contained only 7 to 14 percent of anything resembling the real molecule. She also unpacks the muscle preservation claims that are not backed by human data, the anhedonia and placebo effect reports circulating online, why bariatric surgery comparisons need context, and how to find a reputable source like Midi Health for anyone considering a GLP-1 through legitimate medical channels. Topics discussed: retatrutide, Ozempic, semaglutide, Wegovy, tirzepatide, Mounjaro, Zepbound, GLP-1, GLP-3, Eli Lilly, bariatric surgery, Midi Health, anhedonia, muscle wasting, peptides, BPC 157 Go Beyond The Podcast Join Chalene on her private podcast

In deze extra lange special aflevering zijn we opzoek bij de Boeren van Amstel. Dit is een groep van 18 boeren die houden van hun vak, liefde voor de natuur en toegewijd aan het behoud van groen zo dicht bij de stad. Met het oog op een duurzame toekomst voor het mooie Amstelland zijn de boeren opzoek gegaan naar een alternatief verdienmodel. Daarbij doen ze aan agrarisch natuurbeheer met kruidenrijke graslanden. Dit is een ideaal gebied waar weidevogels kunnen broeden. Dat is een verhaal dat we graag met jullie delen en dus gaan we in gesprek met de verschillende betrokkenen. Maar er wordt natuurlijk ook gevogeld en geloof het of niet, maar Gip ontdekt tijdens deze podcast zijn most wanted vogel en misschien wel de belangrijkste vogel van zijn Big Year. Zie het privacybeleid op https://art19.com/privacy en de privacyverklaring van Californië op https://art19.com/privacy#do-not-sell-my-info.

Stephen Grootes speaks to Ruaan Louw, Managing Director of iDexis, about the company's decision to appeal a recent High Court judgment and regulatory findings relating to its compounding of GLP-1 and GIP medicines. iDexis maintains that its products were safe, says independent testing found no evidence of sterility failures, and argues that regulators were aware of its compounding activities long before the dispute reached court. The Money Show is a podcast hosted by well-known journalist and radio presenter, Stephen Grootes. He explores the latest economic trends, business developments, investment opportunities, and personal finance strategies. Each episode features engaging conversations with top newsmakers, industry experts, financial advisors, entrepreneurs, and politicians, offering you thought-provoking insights to navigate the ever-changing financial landscape.    Thank you for listening to a podcast from The Money Show Listen live Primedia+ weekdays from 18:00 and 20:00 (SA Time) to The Money Show with Stephen Grootes broadcast on 702 https://buff.ly/gk3y0Kj and CapeTalk https://buff.ly/NnFM3Nk For more from the show, go to https://buff.ly/7QpH0jY or find all the catch-up podcasts here https://buff.ly/PlhvUVe Subscribe to The Money Show Daily Newsletter and the Weekly Business Wrap here https://buff.ly/v5mfetc The Money Show is brought to you by Absa     Follow us on social media   702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/CapeTalk 702 on YouTube: https://www.youtube.com/@radio702   CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/Radio702 CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Cheaper obesity medicines could unlock broader demand, while supply-chain bottlenecks and premium-drug innovation may also shape how the market evolves. Our analysts Terence Flynn and Thibault Boutherin break down the investor implications.Read more insights from Morgan Stanley.----- Transcript -----Terence Flynn: Welcome to Thoughts on the Market. I'm Terence Flynn, Morgan Stanley's U.S. Pharma and Biotech Analyst. Thibault Boutherin: And I'm Thibault Boutherin, Morgan Stanley's Europe Pharmaceuticals Analyst. Terence Flynn: Today, how cheaper GLP-1 obesity medicines could reshape access, pricing, and supply chains; and what the first generic markets may signal for Europe and the U.S. It's Monday, July 13th at 10am in New York. Thibault Boutherin: And it's 3 pm in London. Terence Flynn: Around one billion people live with obesity worldwide, including over a 100 million in the U.S. Right now, the introduction of the first lower cost generics of semaglutide, a GLP-1 medicine, in some international markets, could have consequences on affordability and demand. Thibault, what are the first countries seeing the introduction of sema generics? What are the current dynamics, and why should global investors pay attention? Thibault Boutherin: Sure. So, so far generics are being introduced this year in three countries: in India, Canada and Brazil. And if we look at India, this is the first market where the generics are being introduced. The patent for semaglutide expired in March 2026, and 13 companies have launched 26 generics across different formulations: autoinjectors, vials, and pills, which price is lower than the branded drug. And because the India market was quite under-penetrated for GLP-1, we are seeing affordability driving volume expansion. In Canada, two generics have been launched so far. Four other generics are waiting for approval, and more are being filed. And finally, in Brazil, one generic was approved last month, and we are expecting these generics to be launched in Brazil in July. And 17 other generics are in different stage of regulatory review in Brazil, and we would expect more to enter the market by the end of this year. And the reason why we focus on these markets is because we believe they could provide a blueprint for what could happen later in the U.S. and in Europe; in particular for Canada, which shares some characteristics with Europe and the U.S. And the patent for semaglutide will expire in Europe in 2031 and in the U.S. from 2032. Terence Flynn: Great. Maybe on the India front, I know that's at the leading edge. What happened with patient demand when price came down? Thibault Boutherin: Sure. So, what we saw in India is a surge in volume when generics were launched, and the volume in April 2026 were already six times higher than the volume in February. And that expansion has been driven mostly by these generics launch, which captured 80 percent of semaglutide volume in April. And our India team expect that the GLP-1 market in India will actually expand in value from $125 million in [20]25 to more than $1 billion by 2030, despite lower prices as we see better, you know, greater volume and greater adoption of GLP-1s in India. Terence Flynn: The other thing, you know, you and I have discussed is the supply chain, and one of the questions is the ability of some of the generic manufacturers to scale semaglutide. So, maybe talk to us about the current capabilities. And could we see bottlenecks in the supply chain formation here? Thibault Boutherin: Yeah, sure. So, there are three key elements to watch on the supply chain. The first is the active pharmaceutical ingredient or API, and that's the semaglutide molecule itself. The second element is the device and the device components, and the third element is the fill and finish, which is basically putting all of these things together. On the API side, so semaglutide molecule, we believe there will be no bottleneck in supplying for generics as we see a handful of large Chinese companies, out of China, building multi-ton capacity for semaglutide. So, we believe there will be no shortage of API to supply the generic supply chain for injectables. On the device, these are the same device companies that are supplying the branded version of semaglutide, and other GLP-1s for the device that are also supplying the generic makers. And we are seeing meaningful investments being made, so we don't believe there will be a bottleneck here. Where we could see a bottleneck emerging is on the fill and finish side. Fill and finish requires highly controlled clean room space to minimize contamination. It requires regulatory approval, and it takes up to three years to build fill and finish capacity. And so, that's where if there is not more investment being made over the next few years, there could potentially [be] a bottleneck emerging for the generic companies. Terence, while semaglutide generics will definitely represent a challenge for the existing branded version of this GLP-1, there are some insights in these emerging dynamics that suggest that tirzepatide, the other GLP-1, could be less at risk. Can you touch a bit on some of these dynamics? Terence Flynn: Absolutely. So, just to remind listeners that semaglutide targets a pathway called GLP-1. Tirzepatide actually targets two pathways. The first is GLP-1, and the second is GIP. And there are some data comparing these molecules, both in Type 2 diabetes and obesity. And tirzepatide gives not only better efficacy but also improved tolerability. And so, what you're seeing in some of the ex-U.S. markets is segmentation, where there are some consumers that are willing to pay a premium price for tirzepatide. Our team in Brazil has done a lot of work on this front looking at this dynamic and, you know, we expect that to play out in many geographies. So, despite the entry of lower-cost generic versions, we think you will still see segmentation of the market between differentiated brand and the lower-cost generics. And that as a result, you will continue to see branded growth.In the U.S. right now, market share is about 60 percent in favor of tirzepatide. And so again, you're seeing a differentiation between these two molecules. Thibault Boutherin: And beyond the introduction of generics GLP-1s, there are other dynamics in the industry that are driving this market. And the introduction of oral drugs this year has been a big topic. Terence, what are your views on the role that orals could play on the market? Terence Flynn: Yes, as a lot of people are probably aware, the many of the existing GLP-1 medicines are injectable. And so those are delivered once a week with a needle. But there are now additional oral options of these GLP-1 medicines. They started off first for Type 2 diabetes, but they have now broadened into obesity as well, following some recent FDA approvals. And what we're seeing is that the introduction in the U.S. so far is expanding the market. So, the majority of people that are taking the oral versions of these medicines are new users to GLP-1s. So again, you're getting market expansion. When you think about the orals as well, one of the other questions is capacity. I know, Thibault, you were talking about the supply chain. There are similar questions for these oral medicines because not all of the oral medicines are the same. Some are easier to manufacture than others, and as a result, that's another variable to consider. So, some of these are what's called peptide-based orals, and some of these are non-peptide-based orals. And the non-peptide-based orals are much easier to scale, for a larger global market. And so that's definitely another variable that we're monitoring and that I think investors need to consider. Thibault Boutherin: And beyond the pill versions of these GLP-1s, we are seeing more innovation in the drug pipeline of the industry, which could be a key driver of differentiation against the competition from the generics. So, what are we seeing emerging today from diabetes and obesity pipelines, which could be exciting for the future of the category? Terence Flynn: So, as we see time and time again in pharmaceutical markets, the key players continue to innovate to try to improve profiles of the existing medications. So, there are, you know, kind of two areas. One would be efficacy; another would be safety tolerability. And so, there are a number of players that are working first to develop longer acting medication. So, as I mentioned, the existing injectable drugs are dosed once weekly. But there are a number of companies that are working to develop potentially monthly or less frequent injections. So, that's one area that we're monitoring closely. And then the second, and again, this plays into what I discussed on tirzepatide, is additional pathways that are involved here in diabetes and obesity, and a number of players are working to target additional pathways beyond GLP-1 and GIP. And so, some of the leading pathways that are being studied are something called amylin and glucagon, and there are a number of medications that are in the late-stage pipeline that are coming along, which have some pretty interesting data. And so that's another area that we're watching. And again, the goal there would be to either improve efficacy and/or improve tolerability versus the existing medications. Thibault Boutherin: Great. And maybe we can also take this opportunity to talk about some of the short-term drivers in the market that are not facing generic today, like the U.S. So, what could be, you know, the key drivers for growth of GLP-1s and the overall obesity and diabetes category over the next five years? Terence Flynn: Yeah, obviously the key one is seeing additional uptake of these medicines. I think right now we estimate, again, obesity in particular, there's about low double-digit percent uptake. And so obviously seeing increasing uptake of these medicines. The orals, as I mentioned, are already driving market expansion. And then the third is access. So obviously in any market, that's very important. In the U.S., I think about 50 percent of employers cover these medications right now. We expect that to increase in the years ahead as the data continues to build. But then this year starting very shortly, the patients in the Medicare program in the U.S., so those people over the age of 65, will be able to access these medicines for $50 per month. And so, we think that is another driver of growth – is this will broaden access to about an additional 18 million people, starting this summer. So, the next phase of the diabesity market comes down to execution, lower cost and scaled supply in the mass market, and innovation and differentiation to compete in the premium segment. Thibault, thanks so much for taking the time to talk. Thibault Boutherin: Great speaking with you, Terence. Terence Flynn: And thanks for listening. If you enjoy Thoughts on the Market, please leave us a review wherever you listen and share the podcast with a friend or colleague today.

Send us Fan MailPeptides are suddenly the hottest word in weight loss clinics, gyms, and wellness circles, but most people are hearing the hype without the definitions, the evidence, or the safety guardrails. Speaking of Women's Health Podcast host Holly Thacker, MD sits down with Layth Tumah, MD, a Cleveland Clinic physician board certified in family medicine, obesity medicine, lifestyle medicine, and trained in functional medicine, to explain what peptides actually are: short chains of amino acids that act as powerful signals in the body, sometimes in ways that look a lot like hormones.They get practical about the peptides people are most likely to encounter through their doctor: GLP-1 and GIP based medications used for diabetes and medical weight management. They clarify how the same underlying drug can be sold under different brand names depending on the indication, why shortages fueled interest in compounding pharmacies, and when compounding is a reasonable tool versus a risky shortcut. They also talk about the deeper “why” behind today's metabolic disease surge and why these therapies can matter for health span, not just the number on the scale.They end where real prevention always starts: food, movement, sleep, stress coping, and connection, plus the reminder that there is no "free lunch" when it comes to powerful supplements. Support the show

Send us Fan MailFreedom is not just a political idea, it's also the ability to move through your day with energy, confidence, and choices that are not dictated by symptoms or chronic disease. We connect America's 250th anniversary theme of “life, liberty, and the pursuit of happiness” to a very current women's health reality: the obesity epidemic and the frustration many midlife women feel when weight changes collide with hot flashes, sleep loss, and brain fog.We break down common myths around menopause and weight, including the claim that menopausal hormone therapy causes obesity, and we explain what the research actually shows. Then we step into the fast-changing world of weight loss medications, from older drugs that were removed from the market to today's GLP-1 and GIP agents. Then we zoom out to something many people underestimate: social connection as a true health intervention. Social Wellness Month is a reminder that loneliness can harm health in ways that resemble other major risk factors. We share practical ways to build deeper relationships, volunteer, use technology wisely, and create summer traditions that strengthen community. You'll also get healthier July 4th menu ideas, simple recipe inspiration, and summer safety reminders from hydration to fireworks.Follow the show so you do not miss what's next, share this with a friend who needs a reset, and leave a review to help more women find evidence-based health guidance.Support the show

Send us Fan MailOBGYN Dr. Richard Myers joins Dr. Erich Schramm to discuss the name change from Polycystic Ovarian Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS). This syndrome is the combination of three parts: increased polyendocrine hormones (like insulin and androgens), changing metabolism, and differences in ovarian function Dr. Myers explains that the name change to PMOS reflects the changing understanding and focus of the syndrome from a purely ovarian-centered approach to a more holistic, full-body treatment regimen. The doctors also discuss how different patient desires drive different treatment options and the need for individualized, patient-centered care. They finish by looking at new treatments, including GLP-1 and GIP medications that can help address the underlying metabolic components of the PMOS.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Welcome to the latest episode (July 2026) of DOC Updates, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease. This month on DOC Updates: Aroda V, Buzzetti R, Dalskov S et al. "Efficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study." The Lancet Diabetes & Endocrinology, 2026; 0 doi: 10.1016/S2213-8587(26)00126-9 Bajaj H, Welch M, Shah P et al. "Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial." The Lancet, 2026; 407, 2402-2413 doi: 10.1016/S0140-6736(26)00967-0 Melville, N. "CGM Monitoring Benefits Extend to Non-Insulin-Using T2D." Medscape, June 07, 2026 Aronne, L.J., Horn, D.B., le Roux, C.W. et al. "Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial." Nat Med(2026) doi: 10.1038/s41591-026-04386-7 Salive ME, Tjaden AH, Ames JR, et al. "Lifestyle and Metformin Interventions and Risk of Multimorbidity in Adults With Prediabetes." JAMA. Published online June 15, 2026. doi:10.1001/jama.2026.8492 Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health For information about the American Diabetes Association's scholarly journals, visit diabetesjournals.org. For more about this podcast, visit About Diabetes Core Update.

Sarah Kennedy of Calocurb explains why food noise spikes in perimenopause: falling estrogen raises cravings while the hindbrain overrides forebrain willpower under stress or poor sleep. She contrasts natural appetite hormones (GLP-1, GIP, CCK, PYY) with pharmaceutical GLP-1 agonists, which run at roughly 3,000% physiological levels versus the body's natural 300% rise - explaining rebound hunger after stopping injectables. Calocurb, a hops-derived bitter compound, stimulates a 600% natural hormone rise for an 18% average calorie reduction. WHAT YOU'LL LEARN Why food noise isn't a willpower problem, and what's actually happening in your hindbrain versus your forebrain when cravings take over How declining estrogen in perimenopause changes your calorie needs even as cravings increase What GLP-1, GIP, CCK, and PYY actually do in your body, and how they differ from each other How pharmaceutical GLP-1 agonists compare to your body's own natural hormone levels, and what that gap means for nutrient intake Why coming off a GLP-1 medication can trigger intense rebound hunger, and what's happening hormonally during that transition How bitter taste receptors throughout your gut influence appetite signaling, and why this evolutionary mechanism matters What role the luteal phase, travel, and sleep deprivation play in cravings, and how timing strategies can offset them TIMESTAMPS 00:00 - Intro  00:58 - Willpower vs. Biology: The Hindbrain-Forebrain Battle Driving Cravings  04:58 - GLP-1 Explained: How Natural Appetite Hormones Actually Work 10:21 – Supraphysiological Dosing on GLP-1 Drugs and Nutrient Sufficiency Risks  14:03 – Bitter Taste Receptors: The Gut-Brain Mechanism Behind Appetite Suppression  16:58 – Managing Mindless Snacking, Grazing, and the "Licks, Sips, and Dips" Problem  22:06 – Using Appetite Support Strategically During Weight Loss Plateaus  26:26 – Onboarding, Dosing, and Managing Digestive Side Effects  28:13 – Blood Sugar Regulation and New Clinical Research on Weight Loss Outcomes  30:51 – Why You Must Transition Off GLP-1s Strategically to Avoid Rebound Weight Gain  36:53 – Mood, Motivation, and the Liberating Effect of Quieting Food Noise  39:44 – Closing Thoughts VALUABLE RESOURCES• Take the BioSyncing Quiz to help you understand what's actually happening in your body — and how to fix it.

In this podcast, Jennifer Green, MD, and Jay H. Shubrook, DO, FAAFP, FACOFP, share strategies for integrating incretin-based therapies in type 2 diabetes (T2D) management in the primary care setting, including: Importance of moving beyond a glucose-centric approach to T2D care  Current evidence for incretin-based therapies in T2D Rationale for integrating these therapies into the primary care setting Shared decision-making strategies to discuss optimal T2D treatment options with patients Timing for endocrinology referral Presenters: Jennifer Green, MD Professor of Medicine Division of Endocrinology Duke Clinical Research Institute Duke University School of Medicine Durham, North Carolina Jay H. Shubrook, DO, FAAFP, FACOFP Professor, Diabetologist Department of Clinical Sciences and Community Medicine Touro University California, College of Osteopathic Medicine Vallejo, California Full program link: https://bit.ly/4uSKCqv Get access to all of our new podcasts by subscribing to the Decera Clinical Education Multispecialty Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Nee, maak je geen zorgen Arjan blijft nog voorlopig nog gewoon als number one gids en mentor van de Vogelspotcast. Maar we hebben dit keer wel een speciale aflevering. We gaan namelijk op pad met Waldemar. Waldemar is 13 jaar en een van de jongste fans van de Vogelspotcast. Als klein jongetje ging hij al mee op excursies met ons en nu zit die al op de middelbare school. Wat gaat de tijd toch hard. Maar Waldemar is niet zomaar een hobby vogelaar. Hij vertoont dezelfde trekjes die Arjan op zijn leeftijd had; het liefst voor en na school vogelen, elk moment van de dag met vogels bezig zijn, al zijn vakanties staan in het teken van nieuwe soorten en hij werkt al langzaam aan zijn zelf ontdek lijst. Kortom, de nieuwe Arjan in de dop. Ook volgt hij Gip's Big Year op de voet en hij zag dat hij nog een paar soorten miste die hij veel ziet op zijn local patch. Dus heeft die ons benaderd om een aflevering op te nemen. Nou dat konden we niet afslaan. En sterker nog het was zo succesvol dat h et een dubbele aflevering is geworden. Gip heeft iig weer wat soorten op zijn lijst en daar gaat het per slot van rekening om dit seizoen.Partnerships: Sprinklr is dé pionier in het aanbieden van biologische tuinplanten en werkt met maar liefst 17 biologische kwekers samen om het grootste aanbod gifvrij geteelde planten aan te bieden. Met de kortingscode VogelspotcastBio krijg je 5 Euro korting. Ga naar LINK en bekijk het prachtige aanbod. Zie het privacybeleid op https://art19.com/privacy en de privacyverklaring van Californië op https://art19.com/privacy#do-not-sell-my-info.

Send a Text Message. Please include your name and email so we can answer you! Please note, this does not subscribe you to our email list, it's just to answer if you have a questions for us. A weight-loss injection with results on par with bariatric surgery? With retatrutide, that is not an exaggeration.Although it's not FDA approved yet, retatrutide is one of the most talked-about medications coming down the line. In this episode, I'm unpacking Eli Lilly's new “triple agonist” medication, which targets three different pathways: GLP-1, GIP, and glucagon.We'll talk about how retatrutide may help curb appetite, support insulin sensitivity, increase energy expenditure, and accelerate fat metabolism.I'll also walk you through the standout clinical trial numbers behind the hype and take an honest look at tolerability, discontinuation rates, and side effects, including nausea, diarrhoea, and vomiting, so you can understand the full picture.ReferencesHarvard Study: Benefits of Micro Walks Cali Boyz BurritosSecure your spot for the September round of The 30/30 Program now (spaces limited).Subscribe to my Youtube channelAll of the information on this podcast is for general informational purposes only. Please talk to your physician and medical team about what is right for you. No medical advice is being on this podcast. If you live in Indiana or Illinois and want to work with doctor Matthea Rentea, you can find out more on www.RenteaClinic.com Not Sure Where to Start With the Podcast? I've Got You.Get my free Podcast Roadmap—a simple guide to help you find the episodes that matter most to your journey. Whether you're on GLP-1s, navigating plateaus, or just starting out, there's something here for you.Support the show

Doctor Mau Informa ®️ #drmauinforma Durante medio siglo, la endocrinología consideró al glucagón como el "villano" del metabolismo: la hormona responsable de subir el azúcar en la sangre. Sin embargo, ¿qué pasaría si pudiéramos domesticar a este villano para activar la quema extrema de grasa de forma segura. En este episodio de Doctor Mau Informa, analizamos la fascinante evolución científica que nos llevó desde tumores pancreáticos hasta el desarrollo del Retatrutide, un revolucionario fármaco "triple agonista". Descubre cómo la ciencia logró combinar tres señales hormonales (Glucagón, GLP-1 y GIP) en una sola inyección semanal para alcanzar resultados de pérdida de peso metabólica que antes solo le pertenecían al bisturí de la cirugía bariátrica. En este episodio aprenderás: → La balanza de la pérdida de peso: Por qué los medicamentos anteriores solo te quitaban el hambre, y cómo la nueva generación también acelera tu gasto energético. → El secreto del Glucagón: Cómo esta hormona del ayuno saca la grasa del hígado y eleva el metabolismo. → La evolución del GLP-1: El papel protector de la insulina natural para contrarrestar el azúcar y permitir una pérdida de peso segura. → Cirugía vs. Fármacos: Por qué los resultados de los nuevos tratamientos crónicos están cambiando el paradigma médico para siempre. → La realidad clínica: Efectos secundarios, la importancia de la titulación médica y por qué esto no es una "dieta milagro".

Lieve luisteraars. Door een fabrieksfout van onze geluidsapparatuur is de derde en laatste aflevering van het Lauwersmeer helaas mislukt. Als troost doen we wel een recap van de aflevering zodat jullie er toch een beetje bij waren. Deze aflevering zijn we in de Groene Jonker, maar ook daar vertoonde onze nieuwe apparatuur weer kuren, waardoor Gisbert's geluidsspoor continu oversloeg zonder dat we dat doorhadden. Het is dus allemaal beetje behelpen zoals u merkt... Maar Arjan heeft er flink aan zitten klussen en daarmee is het ergste verholpen. Maar het is verre van perfect. Toch hebben we besloten om de aflevering live te zetten, want 'the show must go on'. Er wordt namelijk wel veel gelachen en er zijn drie nieuwe soorten voor Gip's Big Year gescored. Hopelijk vergeven jullie het ons en we beloven dat er achter de schermen wordt hard gewerkt aan de audiokwaliteit. Dank voor jullie begrip en hopelijk kunnen jullie toch genieten van deze aflevering. Zie het privacybeleid op https://art19.com/privacy en de privacyverklaring van Californië op https://art19.com/privacy#do-not-sell-my-info.

It's In The News - a look at the top diabetes stories and headlines happening now!   Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcript: fall Detroit and Seattle.   Okay.. our top story this week: XX The FDA approved Tzield for use in stage 3 T1D – that's what we used to just call type 1. It's the stage where the body can no longer produce enough insulin on its own to manage blood sugars you need to start insulin. This approval is for kids ages 8-17 within 8 weeks of a stage 3 T1D diagnosis. It comes after the PROTECT trial and it's the first approval of a disease-modifying therapy for stage 3 T1D. https://www.prnewswire.com/news-releases/breakthrough-t1d-celebrates-approval-of-tzield-for-use-in-stage-3-type-1-diabetes-in-the-us-302799532.html XX Encouraging results from a small study of islet cell transplantation in people with type 1 where now all 12 participants in the trial are currently living without external insulin after receiving transplanted insulin-producing islet cells.   The study, led by researchers at the University of Chicago, tested an experimental immune therapy called tegoprubart Te-GO-Proo-Bart. The drug is designed to prevent the body from rejecting transplanted cells while avoiding some of the side effects associated with standard anti-rejection medications. You've probably heard about this as the Eledon study – many of the participants have been very active on social media. It was presented at ADA. transplants.https://www.breakthrought1d.org/news-and-updates/tegoprubart-islet-transplant-all-participants-off-external-insulin/ XX New data suggest that acmopatide (ack-MOW-puh-tyd) (CT-868), an experimental once-daily dual GLP-1/GIP receptor agonist, may help people with type 1 diabetes improve blood sugar control, lose weight, and reduce insulin use. Across all doses, participants lost up to 7% of their body weight and reduced insulin use by as much as 15%. The study lasted just 16 weeks, so researchers say longer-term data will be needed to determine whether the benefits can be maintained and whether lower insulin requirements can be achieved without increasing the risk of hypoglycemia. XX A new combination therapy that pairs an amylin analog with semaglutide improved both blood sugar levels and weight loss in several groups of people with type 2 diabetes. The once-weekly injectable, known as CagriSema (KAG-ruh-SEM-uh), was evaluated in three Phase 3 REIMAGINE studies. In people early in the course of type 2 diabetes, researchers reported A1C reductions of up to 1.8 percentage points and significant weight loss compared to placebo after 40 weeks of treatment. Investigators also noted improvements in several cardiometabolic risk factors, including blood pressure. https://www.medpagetoday.com/meetingcoverage/ada/121658 XX Stelo for kids is now FDA cleared.. the over the counter Glucose Biosensor System is now approved for children as young as 2 years old who do not use insulin. The FDA identified pediatric prediabetes as a growing public health concern motivating the expanded indication, noting OTC CGMs can help younger users and their caregivers build glycemic awareness, track patterns in response to me https://www.hcplive.com/view/fda-clears-first-otc-glucose-monitor-for-children XX Insulet presented new data from its STRIVE and EVOLUTION 3 studies showing improved glucose control with its next-generation Omnipod 6. That's , the company's upcoming hybrid closed-loop system for people with type 1 and type 2 diabetes. The main difference between the Omnipod 6 and Insulet's current Omnipod 5 patch pumps is that the new system has a lower glucose target of 100 mg/dL and better Bluetooth connectivity Insulet also shared progress on a fully closed-loop system designed specifically for type 2 diabetes. It  does not require carb-counting or insulin bolusing ahead of meals. Physicians also don't need to program the starting settings.   XX Abbott shared new research highlighting challenges in identifying and managing diabetic ketoacidosis (DKA). The studies coincide with the company's development of Libre Duo, a dual glucose-ketone sensor that continuously tracks both measurements. Abbott reported that DKA can be difficult to recognize when patients first arrive at the hospital, based on data from more than 100,000 people. The company has submitted the dual sensor to the FDA and recently received CE Mark approval in Europe. More news from ADA including info from Dexcom, Sequel, Sensonics and the world loses a tireless T1D advocate.. that's all to come right after this. --   Back to the news.. XX   Dexcom announced its acquisition of Nutrisense, a company that combines continuous glucose monitoring with nutrition coaching and behavioral support. At ADA, the company also presented results from the CONNECT study showing significant A1C reductions and improved glucose control in people with type 2 diabetes not using insulin. The findings add to growing evidence supporting CGM use beyond intensive insulin therapy. We did an episode with CEO Jake Leach at ADA about these announcements as well as updates on G8, their hospital product and much more. XX Sequel Med Tech reported positive clinical results evaluating its twiist automated insulin delivery system in people with type 2 diabetes. The study showed improvements in A1C and time in range over 13 weeks XX Senseonics presented new real-world data supporting the performance of its Eversense 365 implantable CGM. The analysis included more than 12,000 sensors and demonstrated sustained accuracy and effectiveness in both open-loop and automated insulin delivery settings. Researchers also evaluated Eversense use with Sequel Med Tech's twiist system. The findings support broader use of long-term implantable CGM technology.   -- MiniMed used ADA 2026 to spotlight two recently cleared diabetes management systems. The MiniMed Flex pump offers a smaller, smartphone-controlled insulin pump option, while MiniMed Go combines the InPen smart insulin pen with Abbott's Instinct sensor. The products received FDA clearance earlier this year. XX Tandem Diabetes Care highlighted data supporting the use of its Control-IQ automated insulin delivery technology during pregnancy. Results from the CIRCUIT trial showed users spent approximately three additional hours per day in the recommended pregnancy glucose range compared with standard therapy. The findings helped support recent regulatory approvals for pregnancy use in both Europe and the United States. Tandem also expanded indications for adults with type 2 diabetes. XX Beta Bionics presented real-world data from the first three years of iLet Bionic Pancreas use. The company reported a 25% improvement in time in range among users, along with positive feedback from clinicians about simplified diabetes management. The iLet system requires only a user's weight to begin therapy and eliminates carbohydrate counting. Beta Bionics also highlighted growing access to near-real-time outcomes through its public data dashboard. XX MannKind presented new findings supporting its Afrezza inhaled insulin at ADA 2026. A post-hoc analysis of the INHALE-1 study found that pediatric users reported greater treatment satisfaction compared with those using rapid-acting injected insulin. The results come shortly after FDA approval expanded Afrezza's indication to include children. We did a bonus episode with one of the lead investigators of the study that lead to that approval. XX Adaptyx presented early clinical data supporting a wearable sensor that continuously measures cortisol levels. The device successfully tracked cortisol changes during both controlled testing and overnight monitoring in first-in-human studies. Company leaders say cortisol plays a major role in conditions including diabetes, hypertension, and depression. The technology uses synthetic DNA-based molecular switches to generate real-time readings.   XX Biolinq shared new clinical findings for its Shine continuous glucose monitoring system. The needle-free device combines glucose monitoring with activity and sleep tracking .The system received FDA clearance in 2025. They're also looking at measuring lactate through the sensor. XX Long-time T1D advocate Kent Schnakenberg died last week. Schnakenberg was known in his community for using his love of bicycling to raise awareness of Type 1 diabetes. He also advocated for improving the lives of those living with the disease. Inspired by his niece, Michelle, who was diagnosed with juvenile diabetes when she was 13 years old, since 2014 he has traveled around the country cycling thousands of miles, speaking to hundreds and hundreds of kids and raising Money. According to Schnakenberg's family, he suffered a head trauma incident in his home on Wednesday. I spoke to Kent years ago – I believe the first year of the podcast. A sad loss but wonderful to see so many tributes and memories posted on social media in the last few days. https://diabetes-connections.com/john-costik-co-creator-of-nightscout-team-schnak/ https://www.wibw.com/2026/06/12/team-schnak-founder-kent-schnakenberg-passes-away/ XX And finally. Alexander Zverev (ts-ver-uhv) won the French Open, his first Grand Slam title. He lives with type 1, he paused a couple of time to check his blood sugar. He was diagnosed at age 4 and partners with Medtronic. "Becoming a professional tennis player was always my dream," Zverev shared in an article posted by Medtronic. "Early on, I was told that competing at the highest level with diabetes was impossible — but my family and I refused to accept that. That's why I'm partnering with Medtronic Diabetes: I want every person with diabetes to feel empowered to live the life they want." He also has a foundation committed to children with type 1 diabetes. Among other things, the life-saving insulin and other essential drugs are provided – also in developing countries." https://www.mensjournal.com/news/alexander-zverev-diabetes-wins-french-open-2026-medical-condition

ADA 2026 delivered a massive wave of obesity and diabetes data, and in this episode of On The Pen, Dave Knapp (@manonthemounjaro) sits down witH ​⁠ to break down the molecules, clinical trials, weight loss results, and safety signals that could define the next generation of obesity and diabetes medicine.We dive deep into Survodutide, Mazdutide, UBT251, Berobenatide (MET-097), CagriSema, Zenagamtide (formerly Amycretin), Petrelintide, and so much more!From GLP-1/glucagon dual agonists to triple agonists targeting GLP-1, GIP, and glucagon, the obesity treatment landscape is becoming more competitive than ever. Which therapies showed the strongest weight loss? Which struggled with tolerability? And what do these results mean for patients living with obesity, type 2 diabetes, MASLD, sleep apnea, and other metabolic diseases?In this episode:✅ Survodutide obesity and liver fat reduction data✅ Mazdutide Phase 3 obesity and diabetes results✅ UBT251 triple agonist weight loss data✅ Berobenatide (MET-097) long-acting GLP-1 updates✅ CagriSema diabetes and obesity trial results✅ Zenagamtide (Amycretin) injectable and oral development✅ Petrelintide amylin agonist info✅ Future GLP-1, GIP, glucagon, and amylin therapiesThe future of obesity medicine is no longer just about who produces the most weight loss. It's about matching the right therapy to the right patient, improving tolerability, and addressing metabolic disease beyond the number on the scale.Read more obesity medicine news at obesity.news

Is retatrutide, the new triple agonist GLP-1, the next big thing in weight loss (or even rapid fat loss)?That depends on how the drug works, what the results are, the reality between the headlines and the evidence, and what happens to your weight when you stop.This episode breaks down retatrutide, the GLP-1, GIP, and glucagon triple agonist behind the largest weight loss numbers ever recorded in this class. It covers the Phase 2 obesity trial and the Phase 3 Triumph results, plus why cross-trial comparisons to semaglutide and tirzepatide deserve skepticism.We examine the body composition data (or lack thereof), and why a bigger number on the scale just amplifies the stakes for muscle mass, weight regain, and the off-ramp. Especially relevant for adults over 40 who are taking, considering, or planning to come off a GLP-1.Enroll in Eat More Lift Heavy, the 26-week coached program where adults over 40 build the nutrition and training skills to preserve muscle, lose fat, and manage their physique for life, including support for lifestyle changes needed while taking GLP-1s (and to come off them if desired).Timestamps:0:00 - Retatrutide and the biggest question for GLP-1 users 3:08 - How this new triple agonist works 4:46 - Phase 2 and Phase 3 weight loss numbers 5:38 - Cross-trial comparisons and their limits 6:23 - Fat, muscle, and what the trial did NOT measure 8:30 - Strength training over 40 and accelerated muscle loss 10:07 - Building the lifestyle (alongside using the drug) 14:10 - Resistance training and protein 16:00 - Rate of loss on a powerful drug like retatrutide 17:30 - The off-ramp when you stop 18:23 - Weight regain and body fat overshooting 22:03 - Retatrutide access and the gray market 24:11 - Bonus: 3-question test to keep your resultsEpisode Mentioned:Sometimes More Is More (The Sedentary Lifter Problem)

Can retatrutide finally be the breakthrough obesity treatment we've been waiting for? The answer is yes—and the data is stunning. In this episode I'm walking you through the biggest obesity medicine discovery from the ADA's 86th Scientific Session: retatrutide, a triple hormone receptor agonist showing weight loss results that rival bariatric surgery. You'll learn what makes retatrutide different from Wegovy and Zepbound, the stunning results from the Triumph 1 trial, what the side effects actually look like, and when this medication will finally be available. Weight loss medications are evolving faster than ever. But what you really need to know is what these results mean for your health. Listen now! Episode Highlights: Retatrutide is a triple hormone agonist that targets GLP-1, GIP, and glucagon receptors Participants lost an average of 28.3% of their body weight in 80 weeks Two-thirds of participants achieved a normal BMI—moved from obese to healthy weight Nearly everyone with prediabetes reversed it and returned to normal blood sugar Over 70% reduction in knee osteoarthritis pain and 60% reduction in sleep apnea severity The highest discontinuation rate due to side effects was only 11%—mainly GI issues Retatrutide is not yet FDA approved but anticipated to launch early 2027 Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Timestamps : 00:00 — Intro — Welcome to the Holistic Kids Show 00:20 —  The Childhood Obesity Crisis: The Numbers 01:14 — Guest Introduction: Ashley Koff, RD 02:12 — Ashley's Personal Story & What Drove Her Mission 04:34 — Rethinking Weight: It's a Signal, Not a Sentence 05:15 — Introducing Your Best Shot & Weight Health 06:07 — Understanding Hormones: GLP-1, GIP, CCK & PYY Explained Simply 08:15 — How Gut Hormones Control Blood Sugar, Appetite & Bone Health 10:16 — The Gut-Hormone Connection: Why Your Microbiome Matters 11:05 — Can Kids Take GLP-1 Hormones? 11:25 — Ozempic, Wegovy & GLP-1 Medications Explained 13:40 — GLP-1 Medications Approved for Kids 10+ — What Parents Must Know 15:28 — 3 Daily Habits to Naturally Balance Your Hormones 17:21 — Habit #2: Eat Like a Race Car — Fueling at the Right Times 18:04 — Habit #3: Move After Every Meal — Why 7 Minutes Matters 22:03 — "Better, Not Perfect" — What That Really Means for Teens 25:00 — The One Nutrition Rule Every Kid Should Know 29:49 — Where to Find Ashley Koff & Her Resources One in five US children lives with obesity — but are we asking the right questions? In this powerful episode, the Holistic Kids crew sits down with Ashley Koff, RD, USA Today bestselling author of Your Best Shot and a leading weight health practitioner with over 25 years of experience. Ashley flips the script on how we talk about weight with kids — moving away from diets, BMI, and body shame, and toward understanding what the body is actually telling us. She explains how hormones like GLP-1, GIP, and PYY are made in the gut lining, why antibiotics and medications can disrupt them for years, and what that means for growing bodies. The conversation also tackles the rising use of GLP-1 medications (like Ozempic and Wegovy) in kids as young as 10 — what the research says, what parents and teens should know, and why these medications are a tool, not a solution on their own. In this episode, you'll learn: Why weight is a signal, not a sentence What GLP-1, GIP, and gut hormones actually do — explained simply How antibiotics and medications affect your hormones for years The truth about GLP-1 medications for kids and teens 3 daily habits to naturally support hormone balance Why BMI is a flawed measure — and what to look at instead The "race car" nutrition approach that keeps your body running better What "better, not perfect" really means for teenagers Guest: Ashley Koff, RD — Founder of The Better Nutrition Program, author of Your Best Shot, recognized by CNN as one of the Top 100 Health Makers.

De tweede dag Lauwersmeer staat in het teken van hard werken voor je waarnemingen. We gaan namelijk een geheel rondje Lauwersmeer fietsen en dat is maar liefst 50km. Maar de sfeer zat er direct goed in, want we waren nog geen 20 minuten onderweg of we werden getrakteerd op het prachtige geluid van de wielewaal. En dan is het zoeken geblazen, want ook al is de vogel knal geel met zwart hij blijft verdomde lastig. Een typisch gevalletje; je hoort hem wel, maar zit hem niet. Maar er staan nog meer knallers op het dagprogramma. Zo moet Gip de Blauwborst nog en de mooiste vogel van Nederland: het baardmannetje. Kortom er is genoeg te beleven met als kers op de taart een vogel die menig deelnemer nog niet op zijn of haar lijst had. Arjan is overigens weer zo fanatiek dat hij zelfs de groep geen koffiebreak gunt, maar gelukkig steekt mooi-weer-vogelaar Gisbert daar een stokje voor. Het moet leuk blijven. En dan nog iets anders: De Vogelspotcast bestaat 5 jaar en dat vieren we met prijzen. Hiep hiep Hoera! Om deze prijzen te winnen vragen we ± 5 minuten van je tijd om een vragenlijst in te vullen. We zouden graaag beter weten wat jullie leuk vinden en wat misschien beter of anders kan. Met jouw antwoorden help je ons om de Vogelspotcast te verbeteren én om meer mensen dichter bij vogels te brengen. Je vindt de vragen lijst op www.vogelspotcast.com/vragenlijst - Alvast heel erg bedankt voor jouw hulp!Ps. Al ruim 700 mensen hebben de vragenlijst al ingevuld! Echt geweldig. Onze dank is gigantisch. Partnerships:1) SNP Natuurreizen gemaakt. Wil je ook op Vogelvakantie. Klik HIER voor hun aanbod2) Vogelbescherming Nederland. Het gaat niet goed met de Steenuil en dat is niet best. Daarom halen we met Gip's Big Year zo veel mogelijk geld op om hier wat aan te doen. Jouw donatie zou enorm helpen. Ga naar www.vogelbescherming.nl/bigyear om te doneren. Alvast heel erg bedankt voor uw steun.Zie het privacybeleid op https://art19.com/privacy en de privacyverklaring van Californië op https://art19.com/privacy#do-not-sell-my-info.

Bongani Bingwa speaks to Dr Siddharth Govender, Medical Director at NADClinic about cracks down on illegal weight-loss drugs, including GLP-1 and GIP medicines, important questions are being raised about what is safe, effective and scientifically proven. 702 Breakfast with Bongani Bingwa is broadcast on 702, a Johannesburg based talk radio station. Bongani makes sense of the news, interviews the key newsmakers of the day, and holds those in power to account on your behalf. The team bring you all you need to know to start your day Thank you for listening to a podcast from 702 Breakfast with Bongani Bingwa Listen live on Primedia+ weekdays from 06:00 and 09:00 (SA Time) to Breakfast with Bongani Bingwa broadcast on 702: https://buff.ly/gk3y0Kj For more from the show go to https://buff.ly/36edSLV or find all the catch-up podcasts here https://buff.ly/zEcM35T Subscribe to the 702 Daily and Weekly Newsletters https://buff.ly/v5mfetc Follow us on social media: 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio7See omnystudio.com/listener for privacy information.

Dr. Spencer and Karl Nadolsky sit down with David W, a nurse practitioner and one of the actual patients enrolled in the Triumph 1 retatrutide phase 3 trial, to break down the data that was just presented at the American Diabetes Association conference and explain why everyone in obesity medicine is paying very close attention. In this episode they cover what retatrutide actually is and why adding glucagon agonism to the GLP-1 and GIP dual agonism of tirzepatide creates a meaningfully different drug with direct effects on liver lipid metabolism, insulin sensitivity, blood pressure, and fat catabolism that you do not see with semaglutide or tirzepatide alone, what David's personal experience in the 12 milligram arm looked like from dose escalation through steady state including the GI side effects that faded by month seven and the heartburn that a low dose PPI fixed quickly, how David went from 240 pounds and a BMI of 35 down to 167 pounds by the end of the trial representing roughly 30 percent weight loss which is right at the trial average, what the Triumph 1 obesity trial found at 80 weeks with the nine and 12 milligram doses delivering nearly 26 and 28 percent average weight loss respectively and almost half of patients on the highest dose losing 30 percent or more, why the 104 week extension data showing patients who stayed on 12 milligrams reaching 30.3 percent average weight loss is being compared to bariatric surgery outcomes, what the Transcend type 2 diabetes trial showed with average A1C dropping to 5.9 percent on the 12 milligram dose in patients who were on no other diabetes medication, why the 41 percent triglyceride reduction and 20 percent LDL reduction are particularly interesting given that the mechanism appears to involve multiple pathways in the liver that tirzepatide and semaglutide do not touch, what the 70 percent reduction in WOMAC knee arthritis pain scores and 60 percent reduction in sleep apnea events mean for patients who have been told their only option is surgery, how Spencer plans to use retatrutide clinically once it is approved and which patients he thinks are the right candidates, why the gray market research peptide version currently circulating is something both doctors strongly advise against, and what Triumph 2 and Triumph 3 are measuring and when that data is expected. The Docs Who Lift podcast distills and simplifies the complexities of exercise, medicine, and weight loss. Subscribe so you never miss an episode. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

We zitten inmiddels in de zesde maand van Gip's Big Year en er staan nu 210 soorten op zijn lijst. Je zou zeggen dat hij goed op schema ligt, maar zo werkt het natuurlijk niet helemaal. Een vogel per dag is in het begin relatief makkelijk, maar het glazen plafond nadert snel in de vogelwereld. Want waar vind je zo snel eigenlijk zeldzaamheden als een woudaap, grauwe kiekendief of smelleken? Gelukkig maken we dit jaar twee buitenlandreizen met SNP Natuurreizen die flink zoden aan de dijk zetten. En in Nederland is ook nog genoeg te vinden, waren we het al snel over eens met hen. Daarom gaan we samen met de Dwaalgasten op Nederlandse vogelreis naar het befaamde Lauwersmeergebied om daar 4 dagen met elkaar te vogelen. De weergoden zijn ons goed gestemd en er zit volgens Arjan een hele bijzondere vogel op ons te wachten!En dan nog iets anders: De Vogelspotcast bestaat 5 jaar en dat vieren we met prijzen. Hiep hiep Hoera! Om deze prijzen te winnen vragen we ± 5 minuten van je tijd om een vragenlijst in te vullen. We zouden graaag beter weten wat jullie leuk vinden en wat misschien beter of anders kan. Met jouw antwoorden help je ons om de Vogelspotcast te verbeteren én om meer mensen dichter bij vogels te brengen. Je vindt de vragen lijst op www.vogelspotcast.com/vragenlijst - Alvast heel erg bedankt voor jouw hulp!Partnerships:1) SNP Natuurreizen gemaakt. Wil je ook op Vogelvakantie. Klik HIER voor hun aanbod2) Vogelbescherming Nederland. Het gaat niet goed met de Steenuil en dat is niet best. Daarom halen we met Gip's Big Year zo veel mogelijk geld op om hier wat aan te doen. Jouw donatie zou enorm helpen. Ga naar www.vogelbescherming.nl/bigyear om te doneren. Alvast heel erg bedankt voor uw steun.Zie het privacybeleid op https://art19.com/privacy en de privacyverklaring van Californië op https://art19.com/privacy#do-not-sell-my-info.

Description:  How do GLP-1 receptor agonists or GIP agonists work and what is the impact for my psoriatic disease? Hear dermatologist Dr. Ronald Prussick and cardio-immunologist Dr. Brittany Weber answer such questions and more.           Join host Archie Franklin as he takes a deep dive into the use of GLP-1 receptor agonists and GIP agonists and the convergence of systemic inflammation related to psoriatic disease with renowned dermatologist and Vice Chair of the NPF Medical Board, Dr. Ronald Prussick from Washington Dermatology Center in Rockville and Frederick, MD, and, cardio-immunologist Dr. Brittany Weber, Director of the Cardio-Rheumatology/ Cardio-Dermatology Program at the University of Texas Southwestern. Learn more about the use of incretin hormones, the impact of weight management on psoriatic disease, metabolic and cardiovascular risk, as well as results from the TOGETHER-Pso and TOGETHER-PsA clinical trials.  This episode addresses the actions of incretin hormones (GLP-1 receptor agonist and GIP agonist) and how such use may be beneficial in the management of inflammation related to psoriasis and psoriatic arthritis.  Thank you to Lilly for their support of this program activity.  Timestamps: (0:00)  Intro to Psoriasis Uncovered & guest welcome dermatologist Dr. Ronald Prussick and cardio-immunologist Dr. Brittany Weber.  (1:35)  What are incretin hormones and how GLP-1 or GIP receptor agonists (RA) inhibit appetite to initiate weight loss. (3:29)  Why GLP-1 RAs are of interest in the management of psoriasis and psoriatic arthritis. (5:23)  The metabolic, cardiovascular, and psoriatic disease convergence. (7:19)  Will reduction of inflammation impact cardiovascular risk? (10:59) Treatment challenges associated with having psoriatic disease and being overweight or obese. (13:45)  Key points around the use of GLP-1 receptor agonists when managing psoriasis and psoriatic arthritis. (17:06)  Results of the TOGETHER-PsO and TOGETHER-PsA phase 3 clinical trials combining use of an IL-17 inhibitor and a GIP and GLP-1                receptor agonist therapy. (19:07)  Having the conversation of adding a GLP-1 RA medication to a treatment regimen. (22:40)  The paradigm shift of GLP-1 receptor agonists and the impact they can have on shared inflammatory pathways. Key Takeaways: ·       Glucagon-like peptide-1 (GLP-1) receptor agonists and glucose-dependent insulinotropic polypeptide (GIP) agonists are two incretin hormones that assist in managing excess body weight -- which as a result can be helpful in managing inflammation in the body.   ·       Psoriasis isn't just a skin and joint disease. It's a complex network of systemic inflammation with shared inflammatory pathways that worsens with increased weight impacting the severity of the disease, and accelerates the risk of metabolic dysfunction, and cardiovascular disease.   ·       The best outcomes occur as a result of multidisciplinary collaboration to address the impact of excess weight and systemic inflammation. If you are struggling to lose weight with diet and exercise, speak with your medical team about your options including the use of GLP-1 or GIP agonists.   Guest Bios: Renowned dermatologist Ronald Prussick, M.D., Medical Director of the Washington Dermatology Center in Rockville and Fredrick, Maryland, specializes in the treatment of psoriasis along with other diseases of the skin, hair, and nails. Dr. Prussick is also a Clinical Associate Professor in Dermatology at George Washington University in Washington, D.C.. Dr. Prussick has a research interest in the impact of diet on psoriatic disease and metabolic health, first becoming interested after being involved in Dr. Joel Gelfand and Dr. Nehal Mehta's work in vascular inflammation trials using FDG-PET/CT scans to view systemic and cardiovascular inflammation associated with psoriatic disease. Dr. Prussick has since participated in the development of the 2018 Dietary Recommendations for Adults with Psoriasis or Psoriatic Arthritis and more recently the position statement "GLP-1 Receptor Agonists in Psoriasis: A Primer from the National Psoriasis Foundation Medical Board". Dr. Prussick is Vice Chair of the NPF Medical Board which provides clinical direction, treatment guidance, and education oversight to the organization and its Executive leaders.  Brittany Weber, M.D., Ph.D. is a cardio-immunologist who is the Director of the Cardio-Rheumatology/ Cardio-Dermatology Program at the University of Texas Southwestern. She is also a member of the Division of Cardiology, a clinical investigator, and imaging specialist. Dr. Weber's research integrates advanced imaging, molecular biology, clinical trials, and population health to understand how systemic inflammation and immune deregulation drives cardiovascular dysfunction. Prior to joining UT Southwestern in 2025, Dr. Weber served on the faculty at Harvard Medical School and was the Director of the Cardio-Rheumatology Clinic at Brigham and Women's Hospital, a nationally recognized clinic addressing inflammation-related heart disease through collaborative, patient centered care. Dr. Weber is also an author on the position statement "GLP-1 Receptor Agonists in Psoriasis: A Primer from the National Psoriasis Foundation Medical Board". Resources: "The Metabolic Collison and How You Can Take Control with Psoriatic Disease" podcast episode with dermatologist Dr. Ronald Prussick and registered dietitian Danielle Cahalan   "NPF Medical Board Issues GLP-1 Primer for Dermatologists" Press Release "Finding My Path to Managing Psoriatic Disease and Excess Weight" podcast episode featuring dermatologist Dr. Erin Boh, patient advocate Brian Lehrschal, and moderator Jennifer Bomberger. 

Tirzepatide, marketed as Zepbound, mimics the action of GLP-1 and GIP, two hormones naturally released by your gut. These hormones are critical in regulating appetite and how much food you consume. By enhancing the feeling of fullness and reducing hunger, tirzepatide helps support weight loss. Read the Full Episode Transcript: https://pepties.com/common-questions-of-tirzepatide/ Related Links/Products Mentioned: Peptide Podcast Partners Page https://pepties.com/partners/ Buy Peptides online at BioLongevity Labs: Use our link and enter COUPON CODE: PEPTIDEPODCAST  at checkout to receive 15% off your total order:  https://go.biolongevitylabs.com/SH5C Momentous Supplements (we use Creatine, Vital Aminos, Whey Protein) https://crrnt.app/MOME/OqGQOxGA LMNT – More Salt, Not Less.  https://elementallabs.refr.cc/default/u/johnjavit Thorne Supplements (we use Omega-3 with CoQ10, Red Yeast Rice, Zinc) https://get.aspr.app/SH1KvW Organifi Creatine and Shilajit Gummies http://rwrd.io/rlbkajm?c MitoZen (methylene blue for Cognitive Function, Anti-Aging, Mental Clarity) https://www.mitozen.com/ref/cnlwiztypt/ For skin and hair health (Copper Tripeptide-1)  Visit Luminose by Entera for an exclusive offer for Peptide Podcast listeners!  ** Promo code PEPTIDEPODCAST at checkout for 10% off an order or 10% off the first month of a subscribe-and-save. ** https://www.enteraskincare.com/?rfsn=8906839.f93c72 NAD+ Push Patch: https://www.pushpatch.com/

Het spant erom in de laatste aflevering van onze Extremadura reeks: gaan ze de kuifkoekoek vinden of niet... De vogel waar iedereen op hoopte heeft zich tot nu toe nog niet laten zien en naarmate het einde in zicht is, loopt de spanning dan ook flink op. Maar gelukkig is er nog genoeg anders moois te zien. Zo gaan we opzoek naar de oehoe en verschijnt de keizerarend voor een tweede keer ten tonelen. Ook splitst de groep zich voor het eerst op. De ene helft wil nogmaals naar Peña Falcón, terwijl de andere helft een mooie wandeling maakt met als doelsoort de zwarte tapuit. Maar hoe dan ook is iedereen voldaan en kijken we terug op een geweldige week vogelen in Spanje waar we maar liefst 126 nieuwe soorten hebben gezien (waarvan 54 voor Gip's Big Year lijst). Een groot succes! En als we dan ook nog op de valreep de kuifkoekoek vinden, zou dat helmaal mooi zijn. Wie weet... je hoort het in de laatste aflevering.Partnerships: Deze reis is mede mogelijk gemaakt door SNP Natuurreizen. Wil je nou ook naar Extremadura? Kijk dan op de website van SNP en boek deze fantastische vogelreis of naar een andere reis uit hun veelzijdige aanbod natuurreizen.Zie het privacybeleid op https://art19.com/privacy en de privacyverklaring van Californië op https://art19.com/privacy#do-not-sell-my-info.

Deze aflevering begint met een telefoongesprek tussen Arjan en Gisbert. Arjan is natuurlijk razend benieuwd wat er allemaal gebeurd in zijn aanwezigheid ook al houdt hij Gip's lijst nauwlettend in de gaten. Daarna begint de dag met een geweldige wandeling van 10km. Voor de een doorgewinterde Camino wandelaar een "piece of cake", maar voor Christien een helse tocht. Ze houdt namelijk niet echt van wandelen... (best weird, maar prima). En of het een mooie wandeling was en ook nog eens prachtige waarnemingen. Wat wil een mens nog meer?!De volgende dag gaan we naar DE vogelplek van de Extremadura genaamd: Pena Falcon aka de Gierenrots. Deze plek is de natte droom van menig vogelaar en de parkeerplaats is dan ook al aardig vol als we arriveren. En geen woord gelogen. Zodra we uitstappen zijn de eerste zwarte ooievaars al gespot en is het een walhalla aan gieren. Maar ook de kleinere vogeltjes laten zich zien en zo komen we oog in oog met de befaamde blauwe rotslijster. Het is niet beter samen te vatten dan dat het: ontzettend, geweldig mooi is. Luister maar mee!Partnerships: Deze reis is mede mogelijk gemaakt door SNP Natuurreizen. Wil je nou ook naar Extremadura? Kijk dan op de website van SNP en boek deze fantastische vogelreis of naar een andere reis uit hun veelzijdige aanbod natuurreizen. Zie het privacybeleid op https://art19.com/privacy en de privacyverklaring van Californië op https://art19.com/privacy#do-not-sell-my-info.

This episode is sponsored by AquaTru. AquaTru - Go to https://AquaTru.com/ now for 20% off (your purifier) using promo code FLIPPING50. AquaTru even comes with a 30-day best-tasting water guarantee. Other Episodes You Might Like: Previous Episode - Roadblocks Women Experience When They're Doing "All The Things" Next Episode - Rebounding vs Whole Body Vibration After 50 Which? When? Worth It? More Like This - GLP-1 Medications for Weight Loss: A 42-Year Fitness Professional's Honest Take Resources: Don't know where to start? Book your Discovery Call with Debra. Leave this session with insight into exactly what to do right now to make small changes, smart decisions about your exercise time and energy. Use Flipping 50 Scorecard & Guide to measure what matters with an easy at-home self-assessment test you can do in minutes. Optimal weight health in menopause isn't about eating less or exercising more—it's about finally understanding what your body has been trying to tell you.  If you've been frustrated with stubborn weight gain, low energy, or conflicting advice, this conversation will feel like a reset. We're breaking down the truth about GLP-1, gut health, hormones, and why your results may have stalled despite doing everything “right.”  This episode shifts the focus from quick fixes to a personalized strategy that actually works with your body, not against it. Because optimal weight health in menopause starts when you stop guessing and start listening. My Guest: Ashley Koff, RD, is an acclaimed weight-health expert, “Hollywood's Leading Dietitian” featured in InStyle and practitioner for more than 25 years. Koff is leading a transformative movement in personalized nutrition, turning “better, not perfect” choices into practical, sustainable strategies that deliver real outcomes.  She is the founder of The Better Nutrition Program (BNP) and author of USA Today bestselling Your Best Shot, which introduces weight-health hormones (GLP-1, GIP, CCK, PYY) as the regulators of weight health, offering the first-ever assessment of their function and a personalized optimization system—shot or not. Questions We Answer in This Episode: [00:02:35] What does optimal weight management really mean in menopause? [00:07:39] Are you ahead of your time and getting pushback for your approach? [00:03:17] What are GLP-1 hormones and why do they matter? [00:25:11] Is the fear valid that GLP-1 stops your body from producing its own hormones? [00:29:49] Should we be talking about something more important than muscle loss first? [00:31:21] How does cortisol actually influence weight health in menopause? How can women address the connection between cortisol, GLP-1, and weight? If this episode made you flip your workout routine — share it!

Na de voorpret aflevering gaat de reis nu echt beginnen. Direct na het ophalen van de busjes, gaan we op weg naar onze eerste bestemming Trujillo waar we de eerste 3 nachten verblijven. Maar tussen het vliegveld en het hotel zijn genoeg plekken om even te vogelen. Zelfs bij de eerste tankstop blijven we 20 minuten staan omdat we de eerste gieren al zien in de verte. Ja mensen, we zijn begonnen. Daarna volgen er nog een aantal stops waarbij Gip's eerste doelsoort wordt gezien: de kleine torenvalk. En ook al was de reis een tikkeltje vermoeiend, dat heb je nou eenmaal met reisdagen, ploffen we met met een voldaan gevoel en een aantal nieuwe soorten in een zalig bed dromend over alle vogels die we deze reis gaan ontdekken. Het is natuurlijk even wennDe volgende dag bewegen we ons naar het steppengebied rondom Trujillo. Dit prachtige natuurgebied biedt huis aan een paar van de topsoorten die je moet zien, namelijk: Spaanse keizerarend, grote en kleine trap, wit- en zwartbuik zandhoenders, bijeneters en Iberische klapekster. Wel is het even wennen voor Gip zonder Arjan op stap, een deelnemer merkt scherp op dat hij toch een beetje onrustig is. Maar gelukkig is onze enige echte Christien mee als content manager en het blijkt als snel dat ze een waardig vervanger is. Ook laten we deze reeks Arjan niet geheel buiten beschouwing. Gip belt elke dag getrouw met zijn leermeester om de dag te bespreken en tips op te halen. Hoe dit gaat zul je allemaal meemaken in de komende afleveringen, maar we kunnen je een ding beloven: het belooft een spektakel te worden. Partnerships: Deze reis is mede mogelijk gemaakt door SNP Natuurreizen. Wil je nou ook naar Extremadura? Kijk dan op de website van SNP en boek deze fantastische vogelreis. Je gaat er geen spijt van krijgen ;) Zie het privacybeleid op https://art19.com/privacy en de privacyverklaring van Californië op https://art19.com/privacy#do-not-sell-my-info.

https://www.otplinks.comA new GLP-1 and glucagon agonist dropped data that was supposed to rival retatrutide, just without the GIP, and on the surface the results look solid. But that is not the real story. Even when people successfully lose weight, a large percentage gain it back, and for years that has been framed as a failure of discipline or willpower.This episode breaks down new research that helps explain why that happens. A study published in EMBO Reports shows that obesity can leave lasting changes at the cellular level through epigenetics, where gene activity is altered without changing the DNA itself. Researchers found that immune cells remained in a pro inflammatory, metabolically altered state even after weight loss, with some of these changes potentially lasting for years.In practical terms, this means the body does not simply return to a neutral baseline after weight loss. It can continue to operate as if it is still in an obese state, which helps explain why so many people feel like their body is working against them. This shifts the conversation away from personal responsibility and toward biology, reinforcing the idea that obesity is a chronic, relapsing metabolic disease.That distinction matters because it changes how treatment should be approached. If the underlying biology does not fully reset, then short term solutions are unlikely to be effective long term. These medications may not just be tools for losing weight, but part of ongoing management for a system that retains a memory of obesity and requires continued intervention.

Dell’Utri e moglie a processo per i 42 milioni ricevuti da Silvio Berlusconi. Intanto i Gip di Milano annunciano che per un mese e mezzo saranno effettuate solo le attività prioritarie al fine di garantire "i servizi essenziali". Ne parliamo con Sara Monaci de Il Sole 24 ORE. Attentato all’Hilton di Washington. Il commento di Mario Del Pero, docente storia internazionale a SciencesPo, esperto di storia e politica statunitense.

Dr. Spencer Nadolsky and Karl sit down with Dr. Adam Auton, geneticist at 23andMe, to break down a brand new paper using data from over 27,000 people that identified specific genetic variants linked to how well GLP-1 medications work and how likely someone is to experience side effects. 23andMe has over 11 million people in their research database and used voluntary survey data on medication use, dosage, duration, weight loss, and side effects to match against genetic profiles at scale, making this one of the most powerful datasets anyone has brought to this question. In this episode they cover how genome-wide association studies work and why scanning 600,000 genetic variants at once lets researchers find signals they never could have predicted in advance, why the first signal that jumped out of the data was a variant right in the GLP-1 receptor itself and why that was the moment the team knew they were on the right track, why the same variant that predicts better efficacy also predicts a higher risk of side effects and what that tells us about how the drug is being processed, why tirzepatide users showed a separate signal in the GIP receptor that modulates side effects rather than weight loss, why carrying both variants could make someone 14 times more likely to experience side effects on tirzepatide, why genetics explains roughly 10 percent of weight loss variation and what the other 90 percent looks like, why women tend to respond better than men and why diabetics tend to respond less well, what the future of this research looks like including who regains weight after stopping and whether those patterns are genetically predictable, and why heritability is a statistical measure that gets badly misunderstood even by clinicians. The Docs Who Lift podcast distills and simplifies the complexities of exercise, medicine, and weight loss. Subscribe so you never miss an episode. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

On March 28, 2024, the seventeenth session of the Europan architecture, urban planning and landscape competition was held at the Cité de l'Architecture et du Patrimoine in Paris. Anne-Charlotte Depondt was invited to moderate a media moment for conclude of the program, reflecting on the European dimension of the competition.Former winners and members of the Europan 17 jury took part in the debate:John EDOM, architect, anthropologist, New South, international member of the E17 juryYann HOULLARD, architect and urban planner, Collectif MAYA, winning project E17, Défendons les Palantins, France, team based in Spain Nathanael PINARD, architect, Collectif Carré Noir, special mention project E17, The Butterfly Effect, SpainBéatriz SALADICH, architect and landscape designer, Barcelona, jury member E17, special mention project E16 Charlotte SAMPSON, architect HMONP, representative of the "Switch on the swales" project in Graz for E17 AustriaElena TEJERO, architect, winning project E17, BOCAMAR: the seams of the water, SpainAt a time of intensifying global conflict, this was an opportunity to highlight the european building practices and recall the fundamentals of the competition, with its ecological DNA rooted in territories. A rich exchange of ideas from young architects, urban planners, landscape architects and one anthropologist, all working to shape the world of tomorrow. An expert debate that will be invaluable for future applicants to the competition, to reinforce the motivation of those who want to apply outside their own borders, and to create envy! An unprecedented exchange for anyone in search of constructive, resilient solutions.As part of a partnership between Europan and Com d'Archi, we'd like to give you a summary of these exchanges, which Daniel Andersch Architecte & Urbaniste de l'Etat* (State Architect & Urban Planner), Director of the Europan program @GIP, presented to the public.Many thanks to the competition organizers for this invitation and partnership.*Ministère de l'Ecologie, @GIP Europe des Projets Architecturaux et Urbains_EPAUImage teaser DR © EuropanWith the voice of AliSound engineering : Ali Zogheib___If you like the podcast do not hesitate:. to subscribe so you don't miss the next episodes,. to leave us stars and a comment :-),. to follow us on Instagram @comdarchipodcast to find beautiful images, always chosen with care, so as to enrich your view on the subject.Nice week to all of you ! Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

The obesity medication landscape just changed — again. One brand-new pill is already in pharmacies, and five more are in various stages of approval. But the real story isn't the drugs themselves: it's what they're revealing about how your metabolism actually works, and why willpower was never the problem.This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor break down six metabolic medications — two newly FDA-approved and four in the pipeline — covering everything from a flexible new oral GLP-1 pill to drugs that target the brain's central metabolic pathway directly. Dr. Cooper explains the science behind each one, who might benefit, and what the pipeline tells us about the future of metabolic care. This is the most comprehensive drug update the show has done, and it arrives at a moment when the field is moving faster than ever.Key TakeawaysFoundayo (orforglipron), approved April 1st, is the first small molecule oral GLP-1 — no empty stomach requirement, no cold chain, and potentially lower production costs long-term.The amylin hormone may uniquely address both "I'm nourished" and "I weigh enough" signals in the brain — making the amylin pathway a powerful and underutilized target.Retatrutide (Lilly's triple agonist targeting GLP-1, GIP, and glucagon receptors) is showing unprecedented effectiveness plus significant non-scale benefits, including fatty liver reduction — but is still years from approval.The brain's melanocortin 4 receptor is the CEO of metabolism — regulating energy expenditure, appetite, and insulin — and new drugs targeting it represent the deepest intervention yet.Many of these medications are showing weight-independent benefits, including improvements in kidney, liver, cardiovascular risk, sleep apnea, and joint health that have nothing to do with how much weight is lost.Notable Quote"Everybody focuses on appetite, and you just need to eat less. But now with these medications and how they actually affect our biology, it becomes very clear that there's so much more to this." — Dr. Emily CooperLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

For the last year and a half, the talk of construction sites and Bay Street was about a string of violent incidents targeting GFL, the waste management giant, and GIP, its sister construction company. There was suspected arson, vandalism, and executives' homes were targeted in shootings in both 2024 and this past March. Earlier this month, police made an arrest in connection with the 2024 shootings: Ilan Philosophe, the founder of a competing company, Astro Excavating Inc. The Globe's Robyn Doolittle and Tim Kiladze spent the last year and a half reporting on this, including hours speaking with Philosophe before his arrest. Today, they bring us the full story about the shootings, menacing and hostile text messages, and fights over lucrative construction contracts. Questions? Comments? Ideas? Email us at thedecibel@globeandmail.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This conversation dives headfirst into one of the most controversial and least understood side effects of GLP-1 medications, what many are now calling the “Ozempic personality.” In this candid interview, Dr. Spencer Nadolsky joins On The Pen to unpack the growing reports of anhedonia, a flattening of motivation, desire, and emotional highs that some patients experience, especially at higher doses of tirzepatide and similar therapies.What starts as a discussion about how these medications work in the brain quickly turns into something much deeper. We explore how GLP-1 and GIP receptor agonists don't just reduce hunger, they fundamentally alter the brain's reward system, dampening cravings, food noise, and in some cases, the very drive to seek pleasure at all. That is where the idea of the “Ozempic personality” begins to take shape, not as a diagnosis, but as a shared patient experience that is only now being taken seriously.Dave opens up about his own journey, spending years at the highest dose and slowly realizing that while the medication gave him control over food and blood sugar, it also quietly muted parts of his identity. Hobbies faded. Motivation shifted. The highs and lows of life became more… flat. And it wasn't until stepping away that he could see the contrast clearly.Dr. Nadolsky brings clinical perspective to match the lived experience, explaining how this isn't classic depression, but something more nuanced. Patients aren't necessarily sad, they just stop wanting things. He shares how often this shows up in his practice, how he identifies it, and most importantly, how adjusting dose rather than stopping treatment altogether can restore balance.The conversation also raises bigger questions about transparency in clinical trials, what drug companies knew about these “anti-hedonic” effects, and why something so impactful may not have been formally tracked. At the same time, both Dave and Dr. Nadolsky emphasize what matters most, these medications are still life changing, even life saving, but they are not one size fits all.If you've ever felt like something changed beyond just your appetite while on a GLP-1, this is the conversation you've been waiting for. It puts language to an experience thousands are having but struggling to explain, and it gives you something even more important, a path forward.Watch the full interview to understand the reality behind the “Ozempic personality,” how to recognize it, and how to work with your doctor to find your own sweet spot.

This special Tick Boot Camp Podcast crossover features the full International Lyme and Associated Diseases Society (ILADS) webinar recording, “At the Frontlines of Chronic Illness: Conversations with ILADS Experts.” In this dynamic panel discussion, leading clinicians and specialists unpack why Lyme disease and other infection-associated chronic illnesses are so misunderstood, why testing fails so many patients, and what it really takes to heal—brain, immune system, mitochondria, and terrain included. Moderated by Rich Johannesen (Tick Boot Camp), the panel delivers practical insights and hopeful, patient-centered guidance for anyone navigating complex chronic illness—whether you're a patient, caregiver, clinician, or advocate. Featured Panelists Chris Winfrey, MD — Psychiatrist; Medical Director, New Image Wellness Nicole Bell — “The Lyme Disease Engineer”; CEO, Galaxy Diagnostics Tania Dempsey, MD — Medical Director, AIM Center for Personalized Medicine Melanie Stein, ND — Naturopathic Doctor; Author focused on cellular wellness and healing terrain Host/Moderator: Rich Johannesen (Tick Boot Camp) ILADS Intro: Ali Moresco (ILADS) Episode Highlights ILADS Mission and Why This Webinar Matters The webinar opens with ILADS' mission: improving diagnosis and treatment of Lyme disease and associated illnesses through research, education, and policy. ILADS emphasizes physician training and patient-centered care, while also supporting the educational mission of ILADEF. Rich frames the night as a rare opportunity to hear from experts working at the front lines of complex chronic illness—especially for patients who've been dismissed, misdiagnosed, or told their symptoms “don't make sense.” Segment 1: Brain Health, Neuroimmune Illness, and Why Lyme “Feels Like Dementia” Chris Winfrey, MD Dr. Winfrey introduces a core theme: Lyme is not only an infection—it often behaves like a neuroimmune illness. Key takeaways: The brain is a high-energy, high-immune-demand organ, uniquely vulnerable to infection-driven inflammation and toxicity. Lyme can disrupt brain function through: Blood flow issues Synaptic dysfunction Myelin damage Network-level disruption, not just “neurotransmitters” He describes brain function through networks that Lyme can destabilize: Default Mode Network (internal reflection) Salience Network (switching between networks) Central Executive Network (planning/organization) Action Network (execution) Autonomic Network (regulation) Limbic Network (threat/fear response) The result: patients often describe “brain shutdown,” confusion, cognitive impairment, and even dementia-like symptoms. A major reframing: Emotions are not “non-physical.” They are measurable physiological states. Lyme-driven nervous system injury can create emotional disturbance because the biology is disturbed. Segment 2: Poly-microbial Infection, Fight-or-Flight, and the Belief-Healing Loop Winfrey + Rich Discussion Rich frames humans as spiritual, emotional, and physical beings, and asks how chronic infection impacts both body and emotional resilience. Key points: Lyme can cross the blood-brain barrier and affect virtually any organ system. The nervous system becomes a “central battleground,” and measurement is hard because nervous system dysfunction isn't captured well by simple bloodwork. Rich and Dr. Winfrey explore how illness disrupts perception, decision-making, and our ability to interpret the world—especially when gut function and intuition feel “offline.” The healing paradox: Chronic stress and “fighting your way to healing” can backfire. Dr. Winfrey emphasizes that healing requires a parasympathetic state—rest, digest, repair—and that this often involves acceptance, surrender, trust, and safety. Segment 3: The State of Testing—Why So Many Patients Test Negative Nicole Bell (Galaxy Diagnostics) Nicole shares her personal motivation and professional mission: testing determines treatment, reimbursement, and belief—and too many patients are failed by existing tools. Indirect testing (antibody testing): The standard approach relies on antibodies—meaning it depends on the immune system behaving predictably. But Lyme and other stealth pathogens evade and suppress immune responses. Even in controlled research models, two infected subjects can show completely different antibody patterns. Immunosuppression (illness severity, medications like steroids, immune dysregulation) can reduce antibody reliability. Direct testing (pathogen detection):Nicole contrasts Lyme testing with illnesses like COVID—where you use tests that look for the pathogen itself (PCR/antigen), not just antibodies. Why direct detection is hard in Lyme: Pathogens can be low abundance They can be tissue-sequestered Sampling matters Why urine can matter for Lyme: Lyme may not stay in blood, but it can shed proteins/antigens that filter into urine. Galaxy's approach includes methods to capture, concentrate, and detect those markers. New diagnostics focus: Genus-level screening for the “3Bs” (Borrelia, Bartonella, Babesia) Reducing guessing when symptoms overlap and co-infections “masquerade” as each other Segment 4: Immune Dysfunction, Mast Cells, and Why Antibody Testing Can Go Haywire Tania Dempsey, MD (AIM Center for Personalized Medicine) Dr. Dempsey explains the immune system through two major branches: Innate immune system (fast, primitive defense) Adaptive immune system (antibodies, longer-term response) Mast cells as first responders: Mast cells detect “danger” and release inflammatory mediators (histamine and many others). In chronic infection, mast cells can remain persistently activated, releasing hundreds of inflammatory compounds. Why antibody tests fail (two patterns): Immune suppression → insufficient antibody production → false negatives Immune chaos → excessive, inappropriate antibody production → confusing positives - Positive Lyme bands “everywhere” - Positive autoantibodies without classic autoimmune disease patterns - “Everything looks positive” because signaling is dysfunctional Her central philosophy:It's not only about killing the bug. It's about fixing immune regulation so the body can actually clear or control infection. She also names the broader context: modern toxic load (mold, plastics, pesticides, “forever chemicals”) primes the immune system into dysregulation before infections even arrive. Segment 5: Advanced Immune-Modulating Tools Therapeutic Plasma Exchange + SOT Dr. Dempsey discusses therapies she's excited about, especially for complex, stuck cases: Therapeutic Plasma Exchange (TPE / plasmapheresis): Removes plasma (where antibodies, inflammatory mediators, and “garbage” accumulate) Replaces with albumin (and sometimes IVIG) Concept: reduce inflammatory burden + toxic load to reset the terrain SOT (Supportive Oligonucleotide Technique): Molecular targeted approach designed to reduce replication of specific pathogens More targeted than “wide-net” antimicrobial approaches Used strategically after lowering inflammatory/toxic burden She emphasizes: not for everyone, not a universal cure—but promising enough to merit formal publication. Segment 6: GLP-1 Agonists and Mast Cell Stabilization “Brain-melt” moment, revisited Dr. Dempsey explains why drugs commonly known for diabetes/weight loss may have immune benefits: Mast cells have receptors for GLP and GIP hormones Patients showed improvements beyond weight: cognitive function, inflammation, immune stability She describes: Semaglutide (Ozempic/Wegovy) Tirzepatide (Mounjaro/Zepbound) Emerging triple agonists (GLP-1/GIP/glucagon pathways) Her clinical approach has moved these agents earlier in care plans for immune stabilization in select cases. Segment 7: Cellular Healing, Mitochondria, and the Terrain Melanie Stein, ND Dr. Stein brings it home: healing often stalls when we focus only on killing pathogens, but don't repair the cellular damage. Core concepts: Lyme damages cell membranes, disrupting what goes in/out and how cells communicate. It contributes to mitochondrial dysfunction, reducing ATP (energy currency). If cells stay in “alarm mode,” healing remains blocked. Cell membrane therapy and terrain support: IV and oral lipid support (phospholipids, phosphatidylcholine, omega fatty acids) Personalized support based on lipidomic patterns Supportive therapies to reduce oxidative stress and “toxic fats” Focus on signaling safety to the body—so repair can resume Cell Danger Response:A key theme: even after infections reduce, the body may remain stuck in a persistent defense state, requiring cellular and nervous system support to exit “danger mode.” Regulation Before Eradication Panel Reflection Round As the panel closes, several themes converge: Limbic system + autonomic nervous system regulation is foundational “Regulation becomes before eradication” Healing requires safety, predictability, and nervous system calm Chronic illness can block our ability to connect—especially in relationships—because survival physiology dominates Dr. Dempsey adds that limbic retraining / nervous system reset is often the first step she starts with in her practice. Question and Answer Highlights Lyme and Cancer? The panel notes emerging signals connecting tick-borne illness and certain cancers, but emphasizes that more research is needed to determine causality. Herniated discs, connective tissue, and chronic infection The discussion highlights potential links through: connective tissue disruption collagen damage mast cell mediators (enzymes that affect tissue integrity) infection-driven inflammation Cross-reactive antibody results (example: Brucella) The group explains how antibody testing can produce confusing results due to immune dysregulation and cross-reactivity—another reason why interpretation and test methodology matter. Nasal testing / sinus terrain While not a mainstream Lyme diagnostic route, the panel references nasal/sinus colonization (especially with mold-related or chronic inflammatory patterns) as a terrain factor that can influence recovery. Resources Mentioned Center for Lyme Action – State of Lyme Disease Research paper (Nicole Bell collaboration) ILADS Provider Search International Lyme and Associated Diseases Educational Foundation (ILADEF) Donations (supports education and clinician training) Final Message to Listeners This episode is a reminder that Lyme disease and infection-associated chronic illness are not one-dimensional problems. The path forward often requires: better diagnostics immune regulation nervous system support cellular repair personalized care and hope that the body can recover when the right puzzle pieces come together

Today, I'm pulling together some of the most impactful conversations from the last three months on the Podcast. From breaking down the pitfalls of trendy weight loss drugs to uncovering silent heart health risks, and exploring how mitochondrial transplants and trauma healing are rewriting the story of resilience, these moments have truly shifted my perspective on what it means to pursue lasting wellness. Here are the full episodes: #401: Personalization Is EVERYTHING: The New Science of Weight Health, GLP-1s, and Building Lasting Longevity With Ashley Koff #414: Drop Dead Healthy? Why "Fit" Women & Men Still Have Fatal Heart Attacks! l Dr. Regina Druz #419: Origin Of Disease Is Hiding In Your Cells! Doctor Reveals How To Fix It Now l Dr. Natalie Yivgi-Ohana #421: Why You Can't Hack Longevity Until You Heal Hidden Stored Trauma! l Dr. Aimie Apigian #417: Feeling Depressed? Watch This First (It Might Not Be What You Think) l Dr. Cynthia Keller l Ep  Episode Timestamps: Welcome and quarterly recap intro ... 00:00:00 Longevity is about pattern recognition, not single breakthroughs ... 00:00:41 GLP-1s require personalization, not a one-size-fits-all approach ... 00:04:25 GLP-1 hormone assessment and individualized plans ... 00:06:03 Delayed/suppressed GLP-1 function needs lifestyle changes ... 00:08:04 GLP-1 agonists enable, but don't replace, foundational health tweaks ... 00:09:06 Heart health: sick fat disease, inflammation and cardiac risk ... 00:12:30 GLP-1 and GIP peptides have powerful anti-inflammatory effects ... 00:15:35 Menopause amplifies pre-existing heart/metabolic risks ... 00:18:22 Mitochondrial transplants: emerging therapy for rare diseases ... 00:24:04 Every disease linked to—or helped by—mitochondrial function ... 00:27:00 Trauma healing is phased; start with the gentle approach ... 00:31:21 Chronic survival state rewires the nervous system ... 00:40:02 Covid's gut impact can trigger mood issues, fixed with key nutrients ... 00:50:00 Our Amazing Sponsors: Mitopure Gummies by Timeline - These clinically researched gummies support mitophagy to help renew your mitochondria and boost cellular energy, giving you a stronger biological foundation for resilience—visit timeline.com/nat20 to get 20% off. Quantum Upgrade - Supports nervous system balance without wearables or apps—just effortless, 24/7 quantum energy streaming. With 21+ studies showing measurable improvements in stress and cellular function, it's easy to try for yourself. Visit quantumupgrade.io/NAT and use code NAT15 to start the free 15 day trial. Daily Gut Detox by Just Thrive Health – A gentle, science-backed detox powered by clinically proven immunoglobulins that bind and remove toxins while supporting your gut, immune system, and digestion—without harsh flushing or discomfort. Visit JustThriveHealth.com/NAT20 and use code NAT20 for 20% off your order, risk-free. Nat's Links: YouTube Channel Join My Membership Community Sign up for My Newsletter Instagram Dr. Bill Lawrence Episode

What if weight loss has never been the right goal in the first place? In this episode, Dr. Taz sits down with registered dietitian Ashley Koff, RD, author of Your Best Shot, to unpack why the conversation around GLP-1 medications is much bigger than Ozempic, Wegovy, or tirzepatide alone.This episode reframes the entire GLP-1 conversation by shifting away from weight loss as the goal and toward what Ashley Koff calls “weight health.” Instead of treating Ozempic, Wegovy, tirzepatide, and related medications as magic fixes or villains, the conversation explores the deeper hormonal ecosystem behind appetite, blood sugar, digestion, inflammation, body composition, and metabolic health.Ashley explains that GLP-1 and GIP are part of a larger family of peptide hormones made in the gut lining, and that when this system is disrupted by poor digestion, stress, gut lining damage, nutrient insufficiency, dehydration, medications, or microbiome imbalance, the body's weight regulation becomes suboptimal. She argues that many people are not failing at weight loss. Their body simply does not have what it needs to function optimally.If you're dealing with weight changes, food noise, metabolic dysfunction, or feeling like your body is not responding the way it should, and want deeper, root-cause support, join the Circle here: 

GLP-1/GIP Drugs & HRT in Midlife: What the New Data Suggests for Women's Health | The Menopause Master Show | Episode 273 

How Continuous Glucose Monitors Can Optimize Metabolic Health—and Where GLP-1 Drugs Fit: Emergency physician-turned-preventive/metabolic medicine specialist Dr. Paul Kolodzik of Metabolic MD reveals how continuous glucose monitors (CGMs) are a tool not only for diabetics but also for non-diabetics and pre-diabetics to personalize diet, sleep, and exercise by seeing real-time glucose patterns instead of relying on fingersticks or A1c averages. Kolodzik describes CGM use in his clinic (two-week diagnostic wear, then therapeutic guidance), highlights insulin resistance, fasting insulin testing, glucose variability, and the role of low-carb eating, intermittent fasting, and strength training to improve metabolic syndrome, triglycerides, and fatty liver. They discuss CGM sourcing/cost, device mechanics and accuracy, possible future noninvasive wearables, and GLP-1/GIP weight-loss drugs, emphasizing supervised, limited-dose use with protein and lifestyle changes to avoid muscle loss and weight regain. A free PDF of Kolodzik's book is offered HERE.  

Resources for the Community:___________________________________________________________________https://linktr.ee/theplussidezFind Your US Representatives https://www.usa.gov/elected-officials ______________________________________________________________________This isn't medical advice — always talk to your doctor before making any health decisionsIn this episode of The Plus SideZ, we break down the latest GLP-1 news and what it actually means in real life.We're joined by Dave (Man on Mounjaro), who shares his firsthand experience coming off a GLP-1 after years on treatment, while we also unpack emerging research and what's coming next in this space.This conversation covers both data and lived experience, including:• What new studies say about stopping GLP-1 medications • Why benefits may reverse after discontinuation • Real-world weight regain, hunger, and metabolic changes • Mental health and brain-related effects tied to these medications • The difference between GLP-1 and GIP and why it matters • New and emerging medications being studied for neurological and metabolic conditions • Where treatment may be headed next beyond weight lossThis episode connects the dots between science, patient experience, and the future of obesity treatment so you can better understand what's happening now and what may be coming next.Whether you're on a GLP-1, considering one, or thinking about long-term use, this is a must-listen conversation.Guest Host:  Dave Knapp @OnThePenPodcast______________________________________________________________________Join this channel to get access to perks:   / @theplussidez______________________________________________________________________#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide  #GLP1 #Obesity #zepbound #wegovy #ObesityCare #PatientAdvocate #GLP1Community #RealGLP1StoriesSend us Fan Mail! Support the showKim Carlos, Executive Producer TikTokInstagram Kat Carter,  Producer TikTokInstagram 

GLP-1 medications like Ozempic®, Wegovy®, and tirzepatide are dominating headlines—but what if the real breakthrough isn't just the shot, but understanding the body's own weight-health hormones? In this powerful conversation, Dr. Anna Cabeca—triple board-certified OB-GYN and The Girlfriend Doctor—sits down with renowned dietitian and personalized nutrition pioneer Ashley Koff, RD, to unpack the science behind GLP-1, the deeper root causes of metabolic dysfunction, and how we can activate the body's natural appetite-regulating hormones. Together they explore why weight health is about far more than calories or willpower. Ashley shares her personal journey into functional nutrition, the hidden hormonal ecosystem behind appetite and metabolism, and how digestion, gut health, and lifestyle choices influence the hormones that regulate cravings, satiety, inflammation, and metabolic balance. Ashley also introduces the framework from her new book Your Best Shot: The Personalized System for Optimal Weight Health—GLP-1 Shot or Not, revealing why sustainable health comes from personalized strategies—not quick fixes. If you've wondered whether GLP-1 medications are right for you—or how to support your metabolism naturally—this conversation is packed with practical, empowering insights. Ashley Koff, RD is the founder of The Better Nutrition Program, Nutrition Course Director for the UC Irvine Susan Samueli Integrative Health Institute's Integrative and Functional Medicine Fellowship, and faculty at the Integrative and Functional Nutrition Academy. A practitioner for more than 25 years, she is recognized as one of CNN's Top 100 Health Makers and has been called "Hollywood's Leading Dietitian" by InStyle.   In This Episode, You'll Learn: • What GLP-1, GIP, PYY, and CCK actually do in the body • Why weight health is an ecosystem—not just calories in vs. calories out • The hidden role of gut health and digestion in appetite hormones • The "Pizza Framework" for building metabolic health foundations • How lifestyle, timing of meals, and microbiome health influence metabolism • When GLP-1 medications may help—and when foundational health must come first • Practical strategies to quiet "food noise" and improve satiety naturally   Key Timestamps 00:00 – Welcome to The Girlfriend Doctor Show 01:00 – Why GLP-1 medications are changing the conversation about metabolism 03:00 – Ashley's personal story and turning point in nutrition science 09:30 – The gut, trauma, and the origins of metabolic dysfunction 13:00 – What GLP-1 and other weight-health hormones actually do in the body 20:00 – Why digestion and gut health drive hormone balance 23:40 – The "Pizza Framework" for metabolic health foundations 28:00 – How meal timing affects hormones and metabolism 32:00 – Supplements and microbiome strategies that support GLP-1 naturally 36:00 – Ashley's book Your Best Shot and how to personalize your approach   Memorable Quotes 1. Ashley Koff: "Weight health isn't about willpower—it's about physiology. When the body has what it needs, the system works the way it was designed to." 2. Ashley Koff: "There is no one ingredient in the recipe that makes metabolic health work. It's about finding the right recipe for your body." 3. Dr. Anna Cabeca: "We don't just want weight loss—we want weight health: strong, confident, vibrant women living in bodies that feel good." 4. Ashley Koff: "Your digestion is the crust of the pizza. If the crust isn't right, nothing you put on top will work the way it should." 5. Dr. Anna Cabeca: "Willpower is physiologic. When you support your body's metabolism and hormones, your ability to make healthy choices comes back."   Connect With Guest Ashley Koff Instagram: @AshleyKoffApprovedWebsite: https://thebetternutritionprogram.com/about/ Book: Your Best Shot: The Personalized System for Optimal Weight Health – GLP-1 Shot or Not: https://thebetternutritionprogram.com/your-best-shot/ Connect With Dr. Anna Website: https://dranna.comInstagram: https://www.instagram.com/thegirlfrienddoctor/ YouTube: https://www.youtube.com/@thegirlfrienddoctor TikTok: https://www.tiktok.com/@drannacabeca Facebook: https://www.facebook.com/thegirlfrienddoctor

It's In the News, a look at the top headlines and stories in the diabetes community. This week's top stories: Metformin may help stem macular degeneration, retatutride moves forward, T1D and demntia link studied, lots of news from ATTD and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  transcript with links:  Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Who's in Vegas? I'll see you there at the Breakthrough T1D summit this weekend. And we have two Club 1921 events for health care providers and patient leaders happening in April – head on over to the website for more. Okay.. our top story this week: XX Metformin may be linked to the slower progression of age-related macular degeneration (AMD). Among people with diabetes who were older than 55, those taking metformin had a 37% lower chance of developing intermediate AMD over a five-year period compared with individuals who were not using the medication. It's one of the leading causes of vision loss in the US and many other western countries. These researchers now say a clinical trial is the next step. https://scitechdaily.com/scientists-discover-surprising-eye-benefit-of-widely-used-diabetes-drug/ XX new study suggests people with type 1 diabetes may be nearly three times as likely to develop dementia compared with people without diabetes. Similarly, people with type 2 diabetes may have roughly twice the risk of dementia compared with those without diabetes. However, the study found an association rather than proof of causation, meaning diabetes was linked to dementia risk but was not shown to directly cause it.   https://www.usnews.com/news/health-news/articles/2026-03-19/both-types-of-diabetes-increase-dementia-risk XX Researchers in Japan say they've developed an insulin pill… in mice.  The study, published in the journal Molecular Pharmaceutics, tested the delivery of oral insulin by building a carrier peptide called DNP-V. This peptide helps to transport insulin through the small intestine, where protein drug absorption is usually poor. The result was a rapid and significant drop in blood glucose, as well as a sustained (longer-term) decrease. The mice's blood sugar was reduced to near-normal levels. Although the researchers are optimistic about the findings translating to larger therapeutic models, they noted that the results in mice do not guarantee the same outcome in humans, and that more research is needed. https://www.foxnews.com/health/needle-free-diabetes-management-could-horizon-study-suggests   XX   Lilly says it's next-generation obesity drug retatutride cleared its first late-stage trial on Type 2 diabetes patients. The drug lowered hemoglobin A1C by an average of 1.7% to 2% across different doses at 40 weeks compared with placebo, and helped patients lose an average of 16.8% of their weight. Retatrutide also met the study's second goal, helping patients at the highest dose lose an average of 16.8% of their weight, or 36.6 pounds, at 40 weeks, when evaluating only patients who stayed on the drug. When analyzing all participants, including those who discontinued treatment, the highest dose of the drug helped patients lose 15.3% of their weight. The company was also "very pleased" with the relatively low discontinuation rates due to side effects, which were up to 5%, he added. But Lilly has yet to file for approval of the drug for obesity or diabetes. The company expects to report findings from seven additional phase three trials on the drug by the end of the year. Still, retatrutide's A1C reduction doesn't appear to be the greatest Lilly has seen within its portfolio: The highest dose of Zepbound lowered the measure by more than 2% at 40 weeks in two separate trials on diabetes patients. Dubbed the "triple G" drug, retatrutide works by mimicking three hunger-regulating hormones – GLP-1, GIP and glucagon – rather than just one or two like existing treatments. That appears to have more potent effects on a person's appetite and satisfaction with food than other treatments.   https://www.cnbc.com/2026/03/19/eli-lillys-obesity-drug-retatrutide-clears-late-stage-diabetes-trial.html XX   The MiniMed Flex gets FDA approval. Thi is a new design from the company formerly known as Medtronic. It's about half the size* of the MiniMed™ 780G pump, no screen – smartphone controlled – and has the SmartGuard™ algorithm with Meal Detection™ technolog. At commercial launch, MiniMed Flex™ will support the company's newest sensor portfolio, including Simplera Sync™ sensor and the Instinct sensor, made by Abbott. MiniMed also announced the MiniMed™ Forward Program, which allows customers who start on the MiniMed™ 780G system to upgrade to the MiniMed Flex™ system for $0. MiniMed Flex™ is cleared for individuals ages 7 and older with type 1 diabetes, and for individuals 18 years and older with insulin-requiring type 2 diabetes. https://www.prnewswire.com/news-releases/minimed-announces-fda-clearance-of-minimed-flex-the-companys-smallest-insulin-pump-featuring-its-first-smartphone-controlled-design-302716864.html   XX Lots of new out of the recent ATTD conference.. some headlines: New study from the UK shows that Ketone Monitoring Could Significantly Reduce DKA Risks in people with type 1 and type 2. This was a study by Abbott which recently submitted a continuous dual glucose-ketone monitor to the FDA for clearance – if approved, it could be available in the U.S. later this year. -- The first modified insulin producing cells are still working 14 months after transplant – without the need for immunosuppressive drugs. This is from Sana which now plans a study of a new therapy.. same gene-editing strategy with lab-grown, stem-cell-derived insulin-producing cells. -- Protein looks like it helps avoid lows during exercise. Both high and low doses of whey protein before exercise were effective, significantly reducing the risk of hypoglycemia by five to 10 times.   Researchers noted that the body's response to protein was rapid (within 20 minutes), which suggests taking it close to the beginning of exercise could be beneficial for preventing hypoglycemia. Though more research is needed, there was also evidence showing protein intake could be beneficial for prolonged fasting and preventing overnight lows. -- More info about type 1 and GLP medications. Researchers at ATTD presented the results of a small, seven-month study assessing the effectiveness of semaglutide for people with type 1 diabetes and obesity. During the trial, 36% of participants taking semaglutide spent more than 70% of their time in range, less than 4% of their time below range, and lost more than 5% of their body weight compared to those not taking semaglutide.   Treatment with semaglutide was also associated with reductions in cholesterol and blood pressure. Based on all of these changes, the researchers calculated that the participants who received semaglutide had significantly reduced their risk of heart disease over the next 10 years.   Other studies show that since 2020, prescriptions of GLP-1 medications have grown exponentially for adults with type 1 diabetes between the ages of 18 and 85. https://diatribe.org/diabetes-research/top-diabetes-news-attd-2026   XX Lots of talk about fully closed loops.. CamDiab unveiled theirs.. called Liberty.. which the company says it's the world's first fully closed loop commercial launch. CamDiab offers the FDA-approved mylife CamAPS FX app for automating insulin delivery in MyLife's (formerly Ypsomed Diabetes Care's) insulin delivery pumps. The mylife CamAPS FX on iOS has full compatibility with leading continuous glucose monitors (CGMs). Those include the FreeStyle Libre 3 and Libre 3 Plus from Abbott and the Dexcom G6 so customers can use their preferred device. https://www.drugdeliverybusiness.com/camdiab-unveils-fully-closed-loop-insulin-feature/ XX Insulet reported data on a fully closed-loop automated insulin delivery system in people with Type 2 diabetes. The 24 people in the trial spent 24% more time in the target blood glucose range using the system than when receiving standard injection therapy. Insulet plans to start a pivotal study this year and aims to launch in 2028. Rival insulin pump manufacturer Tandem is on a similar course. Tandem CEO John Sheridan told investors on an earnings call last month that his team plans to start a pivotal trial this year to support a filing with the Food and Drug Administration in 2027. Medtronic disclosed the start of a pivotal trial of its Vivera fully closed-loop algorithm last month, shortly before spinning off the program as part of the MiniMed initial public offering. The algorithm, which is designed to eliminate carb counting and manual food bolusing, achieved a mean time in range of 73.8% without manual user input in a feasibility study.   https://www.medtechdive.com/news/insulet-posts-clinical-data-on-fully-closed-loop-insulin-delivery-system/814516/ XX Congrats to all honored by the 2026 National Scientific and Health Care Achievement Awards from the American Diabetes Association! Shout out to Diana Isaacs, PharmD, BCACP, BC-ADM, CDCES: 2026 Outstanding Educator in Diabetes Award and to  Korey Hood who receives the Richard Rubin award. Dr. Rubin was a pioneer in behavioral science and committed to keeping the person with diabetes at the center of research and care.

Join us as we review and appraise recent practice-changing articles. In this episode, we cover the latest in GLP-1s and GIP agonists for CVD, Type 2 Diabetes, and Obesity, valacyclovir to treat Alzheimer's, weight regain patterns after medication-induced weight loss, and a deep dive into the data behind deprescribing – and behavioral science to increase deprescribing behavior.  Fill your brain hole with a delicious stack of hotcakes! Featuring Paul Williams (@PaulNWilliamz), Alex Chaitoff (@alexchaitoff), Nora Taranto (@norataranto), & Matt Watto (@doctorwatto).Claim CME for this episode at curbsiders.vcuhealth.org!Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CMECredits Written and Hosted by: Nora Taranto MD, MSCE; Alexander Chaitoff MD, MPH; Paul Williams, MD, FACP,, & Matthew Watto MD, FACP Cover Art: Nora Taranto MD, MSCE Reviewer: Sai S Achi MD, MBA, FACP Technical Production: Pod Paste Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Show Segments Intro, disclaimer GLP-1 + GIPs vs GLP-1s for patients with T2DM and Obesity – SURPASS-CVOT  Weight Regain after Weight loss  VALAD – Valacyclovir in patients with early Alzheimer's  Nudges to increase Deprescribing  Outro Sponsor: MedStudy Qbank Study less. Remember more. Pass confidently.Medstudy.com/CurbsidersCURB15 for 15% offSponsor: FIGSWe've teamed up with FIGS, and now Curbsiders listeners can get 15% off at Wearfigs.com with code FIGSRX. Sponsor: QuinceRight now, go to Quince.com/curb for free shipping and 365-day returns. Sponsor: A Dangerous DiagnosisTo get 20% off use DIAGNOSIS20 at www.penguinrandomhouse.com/books/808848/a-dangerous-diagnosis-by-shantanu-rai/paperback/

Today, I had the honor of connecting with Ashley Koff. She is a leading voice in personalized nutrition and the founder of the Better Nutrition Program. With over 25 years of experience and the groundbreaking GLP-1 Optimization System to her name, she's helped redefine how we approach sustainable weight health. In our conversation, we dive into how her book reframes the concept of healthy weight. We explore integrative perspectives on digestive health and GLP-1s, why many women blame themselves when they struggle to lose weight, and how Ashley's framework helps them remove that self-blame. We also discuss issues surrounding info-besity and the “less is more” approach, natural ways to support appetite regulation and satiety signaling, key areas of digestive health, and the importance of detoxification. Ashley also shares the red flags she sees in women who are undernourishing themselves or over-fasting, things to consider when you want to stop taking GLP-1s, and her opinions on new drug therapies. Join us for today's thought-provoking and insightful conversation around metabolic health and weight-loss resistance for women in middle age, perimenopause, and menopause. IN THIS EPISODE, YOU WILL LEARN: The interconnection that exists between digestion, hormones, and metabolic signaling How the hormonal fluctuation that occurs in perimenopause disrupts women's digestion What drives satiety?  How GLP-1 medications simply amplify, extend, or mimic an existing communication loop within the body rather than creating new pathways Why do women blame themselves when they cannot lose weight? How info-besity blocks the body from doing what it is naturally designed to do  Why detoxification is essential for supporting natural digestive and metabolic processes The red flags that indicate undernourishment or over-fasting in women What you need to think about before stopping GLP-1s Bio: Ashley Koff, RD, is the USA Today bestselling author of⁠ Your Best Shot⁠ (HarperOne) and founder of⁠ The Better Nutrition Program⁠ (BNP). An acclaimed weight-health expert and practitioner for more than 25 years, Koff is leading a transformative movement in personalized nutrition, turning “better, not perfect” choices into practical, sustainable strategies that deliver real outcomes. Your Best Shot introduces weight-health hormones (GLP-1, GIP, CCK, PYY) as the regulators of weight health, offering the first-ever assessment of their function and a personalized optimization system—shot or not. A trusted expert featured across major media and a sought-after educator for health professionals, Ashley has been recognized as one of CNN's Top 100 Health Makers and featured in InStyle as “Hollywood's Leading Dietitian.” Connect with Cynthia Thurlow   Follow on ⁠X⁠, ⁠Instagram⁠ & ⁠LinkedIn⁠ Check out Cynthia's ⁠website⁠ Submit your questions to ⁠support@cynthiathurlow.com⁠ Join other like-minded women in a supportive, nurturing community:⁠ The Midlife Pause/Cynthia Thurlow⁠  Cynthia's⁠ Menopause Gut Book⁠ is on presale now! Cynthia's⁠ Intermittent Fasting Transformation⁠ Book ⁠The Midlife Pause Supplement Line⁠ Connect with Ashley Koff ⁠The Better Nutrition Program⁠  On ⁠Instagram⁠ and⁠ Substack⁠ On other social media: @Ashley Koff

This episode covers: • Microplastics Are Destroying Male Fertility and Metabolism New research is putting microplastics in a category most men still are not taking seriously: direct reproductive and hormone risk. A 2024 study detected microplastics in every human testicle examined, with polyethylene and PVC among the most common polymers. PVC is especially relevant because it's often tied to chemical additives that can disrupt endocrine signaling. The broader body of evidence points to micro- and nanoplastics crossing barriers like the blood–testis barrier, driving inflammation and oxidative stress in the testes, and showing associations with impaired sperm quality and hormone disruption. The longevity move here is reducing overall load: better water filtration, less plastic food contact, no heating food in plastic, fewer packaged foods, and taking indoor dust and air quality seriously, especially for men thinking about fertility now or hormone resilience over decades. • Sources: – Study (PubMed): https://pubmed.ncbi.nlm.nih.gov/38745431/ – Coverage: https://people.com/microplastics-in-every-human-testicle-infertility-8651215 • Fear of Aging Is Linked to Faster Biological Aging A new study ties aging anxiety to measurable acceleration in biological aging using DNA methylation clocks. People who reported more worry and negative beliefs about aging showed faster epigenetic aging signals, and the molecular differences clustered around stress and inflammatory pathways. In plain terms, chronic threat-mode thinking around aging maps onto biology that looks older on the clocks. For a longevity audience, this is a practical reminder that mental inputs affect physiological outputs. If your day-to-day mindset is constant pressure and decline narratives, that can show up downstream in stress biology and inflammatory tone. A smarter play is building a longevity framework around function, strength, purpose, and community, alongside the usual pillars like sleep, training, and metabolic health. • Source: https://medicalxpress.com/news/2026-02-older-links-health-faster-epigenetic.html • Additional source: https://www.nyu.edu/about/news-publications/news/2026/february/aging-anxiety.html • Retatrutide, the Triple-Agonist Weight-Loss Drug Pushing Bariatric-Level Results Retatrutide is a triple agonist that targets GLP-1, GIP, and glucagon receptors, and the weight-loss numbers being reported are massive. In a 68-week study in people with obesity and knee osteoarthritis, the highest dose group averaged about 28.7% body-weight loss, along with meaningful improvements in knee pain and function. This is the next phase of incretin medicine: multi-agonist drugs that can move body weight by a quarter or more. For biohackers, the performance and longevity angle is implementation: preserving lean mass through resistance training, hitting protein targets, monitoring micronutrients, and building a maintenance plan that doesn't collapse the moment the drug stops. The upside is cardiometabolic risk reduction at scale. The key is running it with structure. • Sources: – Eli Lilly release: https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average – Coverage: https://nypost.com/2026/02/18/health/people-dropped-out-of-retatrutide-trial-for-losing-too-much-weight/ – Background: https://news.harvard.edu/gazette/story/2026/02/whats-next-for-glp-1s/ • AI Can Predict 130 Diseases From a Single Night of Sleep Stanford's SleepFM project shows how much long-horizon health information is encoded in sleep. Researchers trained a foundation model on roughly 585,000 hours of clinical polysomnography data from about 65,000 people. From a single night of sleep study signals, the model could estimate risk for 130 conditions, including dementia, heart attack, heart failure, chronic kidney disease, stroke, atrial fibrillation, and all-cause mortality, and it generalized across cohorts better than simple demographic baselines. The big implication is that sleep architecture and micro-patterns (stage distribution, fragmentation, breathing stability, micro-arousals) function like a dense biomarker stream for systemic aging and disease risk. Expect better sensors and more validated risk dashboards over time. Right now, this is another reason to treat sleep as a core diagnostic pillar, not just a recovery habit. • Sources: – Stanford Medicine: https://med.stanford.edu/news/all-news/2026/01/ai-sleep-disease.html – Paper (Nature Medicine): https://www.nature.com/articles/s41591-025-04133-4 • Living at High Altitude May Protect Against Diabetes by Turning Red Blood Cells Into Glucose Sinks For years, population data has suggested lower diabetes rates at higher elevations. New mechanistic work is pointing to a surprising driver: red blood cells changing how they handle glucose under low oxygen conditions. In hypoxia, red blood cells can behave like glucose sinks, pulling more sugar out of circulation and improving glucose tolerance, which may help explain the protective association seen at altitude. The downstream potential is a new class of altitude-mimetic approaches that target erythrocyte metabolism as a glucose lever, separate from appetite suppression or classic diabetes pathways. For biohackers, it expands the metabolic toolkit and reinforces that oxygen environment and blood physiology matter more than we've given them credit for. • Source: https://medicalxpress.com/news/2026-02-red-blood-cells-sugar-high.html • Dietary Supplement Regulatory Uniformity Act and the Future of Supplement Access A proposed bill is aiming to stop states from layering extra rules on dietary supplements beyond federal law, creating one national standard instead of a patchwork of state-by-state restrictions. Industry groups are supporting it as a way to reduce confusion and compliance chaos, especially as some states explore age limits or special labeling requirements for certain supplement categories. The strategic implication for biohackers is that regulation shapes access. Uniformity can stabilize availability, but it also raises the stakes of federal decisions on controversial ingredients. This is one of those policy stories that quietly determines what stays on shelves, what disappears, and how much innovation survives in the supplement space. • Sources: – NutritionInsight: https://www.nutritioninsight.com/news/npa-crn-supplements-us-fda-legislation.html – Congressional release: https://langworthy.house.gov/media/press-releases/congressman-langworthy-introduces-dietary-supplement-regulatory-uniformity-act – NutraIngredients: https://www.nutraingredients.com/Article/2026/02/05/new-bill-aims-to-end-state-supplement-regulations/ All source links are provided for direct access to the original reporting and research. New episodes every Tuesday, Thursday, Friday, and Sunday. Keywords: microplastics male fertility, microplastics testosterone decline, blood–testis barrier toxins, endocrine disruption plastics, sperm count microplastics, epigenetic age acceleration, fear of aging methylation, biological aging mindset, stress inflammation aging, retatrutide triple agonist, GLP-1 GIP glucagon weight loss, incretin drugs obesity treatment, muscle preservation on GLP-1, SleepFM AI model, sleep disease prediction, polysomnography risk scoring, dementia risk sleep data, altitude diabetes protection, hypoxia glucose metabolism, red blood cells glucose uptake, altitude mimetic therapy, Dietary Supplement Regulatory Uniformity Act, supplement regulation federal preemption, FDA supplement policy, biohacking news longevity, metabolic health optimization Thank you to our sponsors! - HeartMath | Go to https://www.heartmath.com/dave to save 15% off. - BrainTap | Go to http://braintap.com/dave to get $100 off the BrainTap Power Bundle. Resources: • Get My 2026 Biohacking Trends Report: https://daveasprey.com/2026-biohacking-trends-report/ • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/ • Upgrade Labs: https://upgradelabs.com Timestamps: 0:00 – Intro 0:19 – Story 1: Microplastics in Testicles 1:44 – Story 2: Fear of Aging Accelerates Aging 3:30 – Story 3: Retatrutide Weight Loss Drug 4:42 – Story 4: Sleep Predicts Disease Risk 6:34 – Story 5: High Altitude & Diabetes 7:57 – Story 6: Supplement Regulation Bill 9:16 – Weekly Summary 10:51 – Outro See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.